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ABSTRACT
TEMPORAL EXPRESSION OF PROGESTERONE AND
PROTEINS ASSOCIATED WITH PROSTAGLANDIN F2ar
INDUCED LUTEOLVSIS IN SHEEP
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Darren E. Ferguson
University of New Hampshire May 2009
To better understand the events associated with the functional and structural regression of
the corpus luteum (CL), the temporal expression of steroidogenic acute regulatory (StAR)
protein, progesterone (PA), matrix metalloproteinase (MMP)-2 and -9, tissue inhibitor of
metalloproteinase (TIMP)-l and -2, eyclooxygenase (COX)-l and -2 was determined following
three systemic infusions of PGF2ain sheep. Luteectomies were performed at 0 hour (controls) or
at -1,1, 8,16, and 24 hours relative to the third infusion of PGF2«. Plasma samples were also
collected. StAR decreased 60 and 45% at the 16 and 24 hour time points, respectively, while P4
reached a nadir (25%) after the 8 hour time point before rebounding at the 24 hour time point.
MMPs and TIMP-2 were unchanged. TMP-1 decreased 30% at the 1 hour time point. COX-1
was undetectable while COX-2 results were inconclusive. Overall, 25% of sheep underwent
luteolysis after three infusions of PGF2a

x

CHAPTER I

Literature Review
Introduction
One of the major benefits of improving fertility among mammals is increasing
livestock production. Large domesticated animals such as sheep, cows, pigs, goats, and
bison are raised for meat, dairy products, leather, wool, and fertilizer. Other uses include
their use as grazing animals and mechanical labor on farms. Thus, factors that decrease
their fertility can lead to severe economic losses for producers. Therefore, it is essential to
understand the physiological mechanisms that dictate reproductive cycles so that
offspring production is maximized in these animals.

"

Mammals require sexual reproduction to produce offspring. They typically exhibit
either a menstrual (humans and other primates) or estrous (rion-primates) cycle.
Mammals that follow an estrous cycle can be further divided into animals that are
polycyclic, monocyclic, spontaneous ovulators, induced ovulators, spontaneous luteal
phase, or induced luteal phase. Despite such a variety of reproductive modes, the major
organs/glands and physiological events that occur over the reproductive cycle are
common to all mammals. These major events include follicular development, ovulation,
luteinization, and luteolysis. Therefore, studying the reproductive cycle of a specific
species allows us to translate that knowledge across a variety of species.
\
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The present study focuses on the sheep estrous cycle with emphasis on luteolysis.
Before we can study the mechanisms involved in sheep reproduction, this chapter will
review some of the basic components of its estrous cycle. As an overview, the sheep
estrous cycle lasts about 17 days and consists of a follicular phase and a luteal phase
(McCracken et al, 1999). The follicular phase is dominated by structures called follicles
and the steroid hormone estradiol (E2). The end of this phase is characterized by estrus
and ultimately marked by ovulation. Following ovulation is the beginning of the luteal
phase (14 days) which is dominated by the corpus luteum (CL), a structure that secretes
the steroid hormone progesterone (P4). Progesterone production is essential for
maintaining pregnancy. However, if pregnancy does not occur, it is crucial that the CL
regresses so that another cycle can begin.
The process of CL regression is termed luteolysis and is initiated by a hormone
called prostaglandin F2tt (PCTVa). However, the mechanisms by which PGF2« act on the
CL during luteolysis are not fully elucidated. Therefore, the present study focuses on the
expression of matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases
(TIMPs), steroidogenic acute regulatory protein (StAR), progesterone (P4), and
cyclooxygenase (COX) enzymes by the sheep corpus luteum following physiological
administration of PGF2a.

2

The Follicular Phase
The ovarian follicle housing the egg is the dominant structure of the follicular
phase. In primates and ruminants, a female is born with a set number of primordial
follicles. At birth, Blackface and Welsh sheep have approximately 100,000 primordial
follicles per ovary (Land, 1970). At the beginning of the follicular phase, a group of these
follicles is recruited for maturation in response to follicle stimulating hormone (FSH;
Hansel and McEntee, 1977). As they develop, several of them become primary and
secondary follicles; however, only one will mature into a tertiary follicle and finally into
a Graafian follicle while the rest die through a process called atresia. Mature follicles
consist of three main cell types (granulosa, theca interna, and theca externa), a basement
membrane, and an antrum (Hirshfield, 1991). The granulosa cells line the inner periphery
of the follicular basement membrane and they also surround the egg, i.e. cumulus
oophorus. This layer of cells is avascular and is bathed in the follicular fluid of the
antrum (Fraser, 2006). The vascularized theca interna line the outside of the basement
membrane with the theca externa surrounding it.
The hallmark of the mature ovarian follicle is production of the steroid hormone
estradiol -(E2). For a long time, it was thought that theca cells alone from the follicle wall
were the site of E2 synthesis (Mossman, 1937; Corner, 1938; Stafford, 1942; Deane and
Barker, 1952). Later, Falck (1959) showed through a series of elegant experiments, in
which various combinations of theca, granulosa and vaginal tissues were transplanted
into the anterior chamber of the eye, that the theca/and granulosa cells cooperate to
synthesize this hormone. Subsequently, Short (1961) coined the phrase "two-cell theory"
3

to describe this interaction. According to this theory, theca interna cells produce
androstenedione which then diffuses through the basement membrane of the follicle wall
where granulosa cells convert it .to E2 by the enzyme aromatase (Ryan et al., 1968;
Dorrington et al., 1975; Makris and Ryan, 1975; Fortune and Armstrong, 1977; Moon et
al., 1978). In addition, granulosa cells are capable of producing the steroid hormone
progesterone (P4) which diffuses through the basement membrane of the follicle wall
where it can be converted into androstenedione by theca cells. Androstenedione is then
used as a precursor by granulosa cells to make E2 (Hsueh et al., 1984). The production of
androstenedione by theca cells is driven by luteinizing hormone (LH) whereas the
conversion of androgens to E2 in granulosa cells is driven by FSH (Dorrington et al.,
1975; Makris and Ryan, 1975; Moon et al., 1978). Follicle stimulating hormone and LH
are gonadotropins produced in the anterior pituitary gland and they are responsible for
follicular maturation and ovulation (Serially et al., 1971; Clarke et al:, 1987).
Production of FSH and LH depends on the hypothalamic hormone called ,
gonadotropin-releasing hormone (GnRH), which is a part of the hypofhalamo-pituitarygonadal feedback loop (Schally, 1971). Gonadotropin-releasing hormone is produced
within the arcuate nucleus of the hypothalamus. In sheep, GnRH is released in low
frequency, high amplitude pulses early in the follicular phase (Clarke et al., 1987;
Moenter et al., 1991). Therefore, FSH and LH production is relatively low.
Gonadotropin-releasing hormone increases to high frequency, low amplitude pulses in
response to increasing E2 concentrations throughout the follicular phase. As a result,
.
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gonadotropin secretion by the anterior pituitary increases, driving the Graafian follicle
toward ovulation.
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Production of GnRH is regulated mainly by steroid hormones (E2 and P4) and a
light-dark cycle in domestic animals (Downey, 1980). Generally, E2 induces GnRH
production while P4 inhibits it (Moenter et al., 1990; Kasa-Vubu et al., 1992). Since
sheep are short day breeders, reducing amounts of light, either naturally or artificially,
will initiate their estrous cycle by stimulating GnRH synthesis, while increasing the
amount of light will inhibit it (Hansel and McEntee, 1977).
The regulation of FSH throughout the estrous cycle of the sheep is similar to that
of GnRH in that it is also controlled by E2 and P4. Depending^ its concentration and
duration during the estrous cycle, E2 either stimulates or inhibits FSH production
(Downey, 1980). During the luteal phase (Days 0-14), when P4 is the dominant hormone
and E2 is at basal concentrations, low E2 decreases hypothalamic GnRH and reduces
anterior pituitary receptivity to GnRH, resulting in suppression of FSH production (Baird
et al., 1975; Goodman, 1994). As E2 increases during the follicular phase, it stimulates
the hypothalamus to increase GnRH production, and consequently, a rise in FSH is
observed (Jonas et al., 1973; Reeves et al., 1974; Pant, 1977; Dobson and Ward, 1977;
Goodman et al., 1981). Estradiol treatment of anestrous and ovariectomized ewes yields a
similar increase in FSH production (Jonas et al., 1973; Reeves et al., 1974; Pant, 1977;
Dobson and Ward, 1977; Goodman et al., 1981). As follicles mature, there is a positive
feedback loop between E2 and FSH, which continues until they both peak in the middle of
the follicular phase. Increasing E2 concentrations beyond this point by addition of
exogenous E2 will be inhibitory.
In addition to being controlled by E2, FSH production is influenced by a 31 kDa
protein hormone called inhibin, which is present in the follicular fluid of the follicle
-

•
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(Martin et al., 1986). Immunization against inhibin resulted in a rise in FSH
concentrations (Al-Obaidi, 1986; Martin et al., 1986; Clarke et al., 1986; Findlay et al.,
1987; Mann et al., 1990; Larson et al., 1991). Treatment with inhibin decreases pituitary
and peripheral concentrations of FSH, but has no effect on LH (Martin et al., 1986). In
addition to decreasing FSH concentration, treatment with follicular fluid containing
inhibin to cows delays estrus (Quirk and Fortune, 1986). Therefore, FSH is essential for
follicular development.
Follicle development is a complex process. Robertson (1969) suggested that
during the late stages of the follicular phase in sheep, a Graafian follicle is present along
with another follicle that is less mature (subordinate follicle). At ovulation, the Graafian
follicle ruptures and involutes to become the corpus luteuin (CL). Meanwhile, the
subordinate follicle persists through the luteal phase and ovulates in the next cycle.
•
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Similarly, Quinlan and Mare (1931) proposed that the subordinate follicle grows rapidly
just after ovulation from the previous cycle and then grows slowly throughout the "interestrus" period. In contrast, Grant (1934) suggests the subordinate follicle steadily grows
throughout the estrous cycle. These results were obtained by measuring the diameter of
follicles from sheep killed at different stages of the estrous cycle and imply that there is
one wave of follicles per cycle.
A subsequent study involved marking follicles with carbon at different stages of
the sheep estrous cycle to determine their growth pattern was conducted (Smeaton and
Robertson, 1971). Laparotomies were performed early in the cycle (days 6-9) and large
follicles were marked with carbon. Subsequently, laparotomies on the same animals were
performed later in the cycle (days 13-15) and new large follicles were marked.
6

Ovariectomies were then performed 3-9 days after estrus and ovaries were sectioned and
fixed onto slides for observation by microscopy. All carbon-marked follicles regressed
while the corpus luteum contained no trace of carbon, suggesting that it came from a
follicle that rapidly matured into a Graafian follicle after the second laparotomy and
ovulated during estrus. These results suggest that there are three follicular waves during
the estrous cycle in sheep. This hypothesis was subsequently supported by transrectal
ultrasonography (Souza et al., 1998; Bartlewski et al., 1999; Vinoles et al., 1999; Evans
et al, 2000; Duggavathi et al., 2003; Evans, 2003). The transrectal ultrasonography
procedure includes inserting a transducer into the rectum and held face down to maintain
contact with the rectal mucosa. The ovary is then located by hand and scanned at
different cross sections. The images captured by the transducer are used to examine
follicles. The first,cohort of follicles results in one follicle (5 mm diameter) enlarging
from days 6-9, while the second cohort results in one follicle (5 mm diameter) enlarging
from days 13-15 (Smeaton and Robertson, 1971). However, the follicles in both waves
become atretic before the next estrous cycle. The third cohort results in one follicle (5
mm diameter) rapidly growing to 12 mm in diameter between the time of CL regression
and ovulation. This mature follicle is the one that ovulates while the others undergo
atresia. In sheep, there are typically 3-4 waves of follicular growth during each estrous
cycle, with waves emerging every 3-5 days. In addition, transient peaks of FSH precede
each wave (Bartlewski et al., 1998; Evans et al., 2001).
"
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It is thought that dominant follicles acquire certain attributes that enable them to
grow while subordinate ones are destined for atresia. Dizerega et al. (1982) suggested
that the mature or dominant follicle secretes follicle regulatory protein (FRP), which
7
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causes the regression and the eventual death of less mature (subordinate) follicles.
Although the granulosa cells of the follicle secrete FRP, this hypothesis was not
supported by subsequent research. An alternative and more likely hypothesis proposed by
Erickson and Hsueh (1978) is that the mature follicle secretes inhibin, which decreases
FSH through a negative feedback loop. The resulting low concentrations of FSH can not
induce maturation of the subordinate follicles, but are enough to maintain growth of the
;
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dominant follicle. Zeleznik and Kubic (1986) provided support for this hypothesis by
showing that low concentrations of FSH are incapable of recruiting follicles, but are
capable of maintaining growth of the dominant follicle in cynomolgus monkeys. More
recently, Knight and Glister (2006) propose that an autocrine/paracrine role of granulosa
cell-derived activin and bone morphogenetic protein-6 (BMP-6), and a paracrine role of
oocyte-derived growth and differentiation factor-9 (GDF-9), BMP-15, and BMP-6,
induce granulosa cell proliferation and modulate FSH-dependent follicle function.
Differential exposure to these proteins may be one way that follicles become sensitized to
FSH, thus giving rise to a dominant follicle.

Ovulation
In order for the Graafian follicle to rupture, LH initiates a cascade of events which
include degradation of the follicle wall, an inflammatory response, and an immune
response (Walton and Hammond, 1928; Espey, 1980). Preceding ovulation, the apex of
the follicle is present on the ovary surface and a stigma forms. The LH surge causes

8
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rupture of the follicle and release of the egg into the oviduct for fertilization (Gaytan et
j

al.,2005).
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In sheep, while several hormonal factors contribute to ovulation, the central
component is the LH surge at the end of the follicular phase (Hansel and McEntee, 1977).
During the estrous.cycle, there is interplay between steroid hormones and gonadotropins.
Exogenous P4 suppresses the FSH and LH response to GnRH during the post estrus
period in sheep (Hooley et al., 1974). Similarly, Karsch et al. (1977) found that P4
inhibits the LH surge during the estrOus cycle in sheep. Despite a study by Martin (1988)
that suggests P4 has no effect on gonadotropin concentrations, it is largely accepted that
P4 inhibits LH and FSH production (Hooley et al., 1974; Baird et al., 1975; Karsch et al.,
1977; Sarkar and Fink, 1980; Martin et al., 1983). Luteinizing hormone concentrations
are basal throughout most of the follicular phase, but begin to increase 5 hours or 22-26
hours before ovulation and reach a peak (45 ng/ml or 100-2G0 ng/ml) at the time of
follicular rupture (Karsch et al., 1977; Goodman, 1994, respectively). To achieve the LH
surge, an increase in E2 from maturing follicles acts to alter the pattern of hypothalamic
GnRH from low frequency and high amplitude pulses to high frequency and low
amplitude pulses (Moenter et al., 1991). As a result, LH production is increased by the
anterior pituitary. In addition, E2 also acts directly on the anterior pituitary gland to
increase GnRH receptors which increases its responsiveness to GnRH (Reeves et al.,
1971). Blocking GnRH action inhibits ovulation (Evans et al., 1996). Therefore, E2 acting
on both the hypothalamus and the anterior pituitary is necessary for the LH surge and
ovulation.

9
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One pathway set into motion by the LH surge is structural degradation of the
follicle wall and the surrounding extracellular matrix (ECM). The Graafian follicle
consists of an inner layer of granulosa cells bathed in follicular fluid, the oocyte, a
basement membrane, and several layers of theca cells (Hirshfield, 1991). The only way
the oocyte can exit the follicle is for the basement membrane to be breached and for the
surrounding ECM to be disrupted. The ECM of the ovary is composed of fibronectin, ;
entactin, nidogen, vitronectin, and collagens IV and XVIII (Ruoslahti and Pierschbacher,
1987; Luck et al., 1995; Irving-Rodgers and Rodgers, 2006), while the basement
membrane is composed of type IV collagen, laminin, heparin sulfate proteoglycans, and
fibronectin (Birkedal-Hansen et al., 1993). Dispersed throughout the thecal layers are
fibroblasts that become active and start to proliferate in response to the LH surge. These
cells secrete the latent form of the collagenase enzyme matrix metalloproteinase-1
(MMP-1; Bauer et al., 1975). Collectively, matrix metalloproteinases are a family of
enzymes that degrade all components of the ECM (Roy, 2006) and they are activated by
'

•
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'
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serine proteases, such as plasmin, trypsin, and chymotrypsin as well as active MMPs
(Woessner, 1991). Tadakuma et al. (1993) treated rabbits with human chorionic
gonadotropin (hCG) to induce ovulation and examined the presence of MMPs around and
within the follicle. They found that MMP-1 is present in theca interna, theca externa, and
around the apex of the preovulatory follicle. Since it is known that MMP-1 degrades
laminin, fibronectin, vitronectin and collagens I, II, III, VII, VIII, X, XI, the increase in
MMP-1 and corresponding decrease in collagen concentrations at the apex of the
preovulatory follicle (Murdoch and McCormick, 1992; Tadakuma et al., 1993) lead to
weakening of the follicle wall. Indeed, the addition of the synthetic collagenase inhibitor
"
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SC 44463 prevents ovulation in the rat ovary (Butler et al., 1991). Similar to MMP-1,
other MMPs such as MMP-2 and -9 also have the ability to degrade several components
of the ovarian ECM and the follicle wall. Curry et al. (2001) reported that MMP-2 and -9
activities are localized at the apex of the rat follicle around the time of ovulation.
Similarly, MMP-2 in the sheep ovary is a crucial enzyme for ovulation. Russell et ah
(1995) showed that MMP-2 expression increases in ovine follicular fluid as the follicle
approached ovulation. A later study demonstrated that ovaries of sheep that were
immunized against MMP-2 never formed a stigma and failed to ovulate whereas the
control animals formed a stigma and ovulation occurred (Gottsch et al., 2002).
Subsequently, Smith et al. (2005) found that bovine theca cells secrete MMP-2 and -9,
and that both theca and granulosa cells secrete MMP-13 in response to LH. Overall, these
findings and those from others (Espey and Lipner, 1994; Hullboy et al., 1997; Smith et
al., 1999; Fata et al., 2000), show that MMP activity is a component of follicular rupture.
An inflammatory response (Parr, 1974; Espey, 1980; Espey, 1994; Espey and
Litner, 1994, Espey, 1994b, Richards et al., 2002), as manifested by redness and
swelling, accompanies the proteolytic activity during the ovulatory cascade.
Inflammation, whether brought on by infection or disease, involves vasodilation and
increased capillary permeability resulting in an increase in blood flow and an abundance
of serum proteins (Willcox,' 1963; Ebert and Grant, 1974). Lee and Novy (1978) showed
that rabbits treated with LH experienced increased ovarian blood flow when compared to
rabbits treated with the anti-inflammatory indomethacin. Additionally, Zachariae (1958)
and Espey (1978) demonstrated that there is increased capillary permeability in
preovulatory follicles.

;
11

To induce this inflammatory response in the ovary, the LH surge stimulates
prostaglandin production by granulosa and thecal cells as well as fibroblasts (Plunkett et
al., 1975; Erickson et al., 1977; Espey, 1980). Prostaglandins (PGs) are a group of
eicosanoid hormones that cause pain and inflammation (Vane and Botting, 1998;

/

McCracken, 2005). In 1973, LeMaire et al. found that PGF and PGE synthesis increases
after gonadotropin stimulation in rabbits. Prostaglandin F reaches a maximum
concentration in the rabbit follicle by the time of ovulation, while PGE concentrations
continue to increase several hours after ovulation (Yang et al., 1974). Murdoch et al.
(1981) measured the amount of PGF2« and PGE2 in the largest follicles from sheep
ovaries 12 hours before estrus, at the onset of estrus, and 12 hours after estrus.
Prostaglandin E2 concentrations increased from 12 hours before estrus to the onset of
estrus, and then decrease 12 hours after estrus. In contrast PGF2Q. concentrations increased
from pre-estrus to the onset of estrus, and continued to increase 12 hours after estrus.
The prostaglandins, particularly PGF2«, play a central role in ovulation. Inhibiting
prostaglandin production by administration of aspirin or indomethacin prevents rupture of
the ovarian follicle (Orczyk and Behrman, 1972); however, treatment with exogenous
PGF2« reestablishes ovulation (Armstrong et al., 1973). Interestingly, PGE2 inhibits
ovulation in the rabbit (Richman et al., 1974). The difference between PGF2« and PGE2
was further shown by Murdoch et al. (1986), who found that sheep ovaries treated with
the anti-inflammatory drugs isoxazol or indomethacin failed to ovulate. However, the
addition of exogenous PGF2ato ovaries exposed to either treatment restores the ovulatory
process, while exogenous PGE2 has the same effect only on indomethacin-treated ovaries
suggesting that PGF2a is the primary prostaglandin that regulates ovulation. It is
'
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suggested that PGF2a stimulates quiescent fibroblasts to the proliferative and active states
(Espey, 1978). As a result, MMP production by these fibroblasts increases (Dayer et al.,
1976; Dowsett et al., 1976; Lupulescu, 1977; Pettigrew et al., 1978) and, in turn,
components of the follicle wall and-surrounding ECM are degraded, leading to rupture of
the follicle. .
The inflammatory response, as part of the ovulatory cascade, is linked to an
immune response involving a variety of leukocytes (Espey, 1980). Granulocytes, a group
of leukocytes that include basophils, eosinophils and neutrophils, secrete matrix
degrading enzymes such as collagenase, elastase and plasminogen activator. Zachariae et
al. (1958) histologically showed that blood vessels of rabbit follicles contain basophils
two hours before ovulation (during the LH surge), whereas those of precoital rabbits (no
LH surge) lacked basophils. Macrophages, another leukocyte, have also been implicated '
in the ovulatory process. After hCG treatment, macrophages increased 5-fold when
compared to controls and were found mostly around blood vessels in the theca region
(Brannstrom et al., 1993; Brannstrom et al., 1994). Similar to other leukocytes,
macrophages aid in matrix degradation, phagocytosis and destruction of invading
antigens. They also secrete cytokines and chemokines which regulate local immune and
inflammatory responses (Gordon, 1999). The idea that leukocytes play a critical role in
ovulation is further strengthened by Hellberg et al. (1991). Perfused rat ovaries were
treated with LH, leukocytes, or both. Ovulation was not seen in any ovaries treated with
either LH or leukocytes alone; however, ovulation occurred in all ovaries treated with LH
and leukocytes.
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Luteinization
Following ovulation, the raptured follicle collapses and undergoes a structural and
functional transformation to become the corpus luteum (CL; Charming, 1975), a process
known as luteinization. Before ovulation, the FSH peak induces LH receptors on
granulosa cells (Zeleznik, 1974; Channing, 1975; Marsh, 1976). Since the follicular fluid
contains luteinizing inhibitor (LI), there is no effect when LH diffuses into the antrum of
the follicle (Ledwitz-Rigby, 1977; Channing'et al, 1980). With the LH surge, the egg
ovulates and the follicular fluid, along with LI, is released. As a result, LH binds to its
receptors on granulosa cells to stimulate the production of cAMP which, in, turn
stimulates P4 production. At this point, the granulosa and theca cells have undergone a
', change to become cells of the corpus luteum.
During luteinization, granulosa and thecal cells transform into large and small
luteal cells of the CL, respectively. In sheep, small luteal cells contain LH receptors and
produce relatively low concentrations of P4. However, this production is increased by 515 fold in response to LH (Niswender, 2002). Large luteal cells also contain LH receptors
i, and produce high basal concentrations of P4. They produce about 80% of the P4 within
the CL (Niswender et al., 1985); however, they do not respond to an increase in LH.
To support the proliferation and function of the steroidogenic luteal cells,
fibroblasts, endothelial cells, pericytes, and immune cells (Smith et al, 1994; Stocco et
al, 2007) within the CL, a considerable blood supply is needed (Reynolds et al., 2000).
In the follicle, the thecal layer of the preovulatory follicle is vascularized while the
granulosa layer is not. As involution of the follicle and transformation of follicle cells to
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luteal cells occur, angiogenesis, the formation of new blood vessels from pre-existing
ones, is initiated. The mam angiogenic factors within the corpus luteum are vascular
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), endocrine
gland-derived growth factor (EG-VEGF), and angiopoietins (Ferrara et al., 1998;
LeCouter, 2002). These growth factors are made by luteal cells, and they increase MMP
production to break down the remainder of the follicle basement membrane and act as
chemotactic agents to promote endothelial cell proliferation and migration resulting in
vascularization of the new gland (Gospodarowicz et al., 1985; Mignatti et al., 1989;
Berish et al., 2000), Angiogenesis of the ruptured follicle results in a "bloody body", also
known as corpus hemorrhagicum (Shapiro et al., 1980). When angiogenesis is complete,
every luteal cell is in contact with multiple capillaries allowing for maximum delivery of
nutrients to keep up with the demand for P4 production during the luteal phase and the
gland is now a "yellow body" or corpus luteum (Reynolds et al., 2000). Progesterone
production throughout the luteal phase and into pregnancy is essential for inhibiting
uterine contractions (Allen, 1935), thickening cervical mucus, and building the
endometrium for the implantation of the fetus (Zarrow, 1965).

Luteolysis
If pregnancy does not occur, the CL must regress so that another ovarian cycle
can begin. Although the mechanisms of CL regression remain to be fully elucidated,~the
hormone that initiates luteolysis in many species is PGF2Q (McCracken et al., 1972;
Nancarrow et al., 1973; Gleeson et al., 1974; Kindahl et al., 1976; Moeljono, 1976;
'
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Poyser, 1976). Following PGF2«, the CL undergoes functional and structural luteolysis,
which are defined as a decrease in progesterone (P4) production and apoptosis,
respectively (Hoyer, 1998; Stocco et al, 2007). It is reported by some that functional
luteolysis precedes structural luteolysis. In sheep, a decrease in P4 concentration is
observed 5 hours after PGF2a treatment whereas evidence of apoptosis does not occur
until 12 hours after treatment (McGuire et al., 1994). Similarly, functional regression in
cows occurs between 1-8 hours after PGF2a treatment whereas structural regression is not
observed until 12-24 hours (Juengel et al., 1993; Tian et al., 1994). In addition, a decrease
in P4 concentrations can be reversed in vivo and in vitro as long as the structural integrity
of the CL is not compromised (Bender et al., 1978; Fraser et al., 1985; Hutchinson and
Zeleznik, 1985). Although these findings suggest that functional luteolysis precedes
structural luteolysis, the temporal sequence of these two events or the mechanisms of
PGF2a action require further study. Therefore, in the remaining sections of this Literature
Review, the current knowledge of prostaglandins, their synthesis and the mechanisms of
PGF2a action within the reproductive tract, with emphasis on the ovine CL,. will be
discussed.

Prostaglandins:
Prostaglandins (PGs) are members of the eicosanoid family and have a wide
variety of actions within the body (McCracken, 2005). Some are involved in gastric
cytoprotection, luteolysis, vasodilation, and inhibition of platelet aggregation, while
others are involved in glaucoma, vasoconstriction, platelet aggregation, and inducing
sleep and fever. The first two prostaglandins, PGE] and PGFia, were isolated from sheep
• • • / ' • •

16

prostate glands (Bergstrom and Sjovall, 1957; Bergstrom and Sjovall, 1960; Bergstrom
and Sjovall, 1960). As more prostaglandins were isolated from sheep prostate glands,
bovine lung, and human seminal plasma, it was later determined that all prostaglandins
are composed of a 20 carbon lipid skeleton called prostanoic acid (Figure 1; Bergstrom
et al., 1962; Samuelsson, 1963; Samuelsson, 1964; Hamberg and Samuelsson, 1965;
Bergstrom, 1968). Modifications to this structure, such as addition of hydroxyl and
oxygen groups, as well as double bonds, determine the structure of specific
prostaglandins. Examples of specific prostaglandins include PGD2, PGE2, and PGF2a
(Figure 1; McCracken, 2005). The letter after the abbreviation "PG" is based on the
fraction of the extraction in which the prostaglandin resides. For example, PGF2a resides
in the "Fosfat" fraction while PGE2 resides in the "Ether" fraction. The number
associated with it indicates the number of double bonds within the structure, while the
Greek letter denotes the orientation of the hydroxyl groups.
Figure 1. Prostaglandins
Pi ostanoic Acid
COOH.
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Prostaglandin Biosynthesis:
Prostaglandins can be synthesized by any cell that has a phospholipid bilayer and
the appropriate enzymes (McCracken, 2005). Therefore, it is not surprising that
prostaglandins are secreted by a wide Variety of tissues, organs, and glands, such as fat
(Shaw, 1966; Ramwell and Shaw, 1967), adrenals (Ramwell et al., 1966; Ramwell and
Shaw, 1967), ovaries (Euler, 1937), stomach (Bennett et al., 1967; Cochani et al., 1967),
intestines (Sukuki and Vogt, 1965; Ambache et al., 1966), spinal and phrenic nerves
(Ramwell et al., 1965; Ramwell et al., 1966). They are also present in the uterus (Karim
and Devlin, 1967), lung (Bergstrom et al., 1962; Samuelsson, 1964), thymus (Bergstrom
and Samuelsson, 1963), brain and spinal cord (Samuelsson, 1964; Cochani and Wolfe,
1965; Ambache et al., 1966; Holmes and Horton, 1967; Horton and Main, 1967), kidney
(Lee et al., 1965; Lee et al, 1966; Strong et al., 1966; Daniels et al., 1967), iris (Anggard

and Sarauelsson, 1964; Ambache etal., 1966; Wattman et al., 1967), and umbilical cord
(Karim, 1967). ,
-''

,

Prostaglandin synthesis begins with the enzyme phospholipase A2 (PLA2)

cleaving a 20 carbon structure called arachidonic acid (AA) from the cell membrane; The
free AA serves as the precursor for all eicosanoids (McCracken, 2005). The PLA2 family
includes three forms: cytosolic PLA2 (CPLA2), secretory PLA2 (SPLA2), and calciumindependent PLA2 (1PLA2; Diaz and Arm, 2003). Cytosolic PLA2 and SPLA2 are
considered to be the primary enzymes that regulate eicosanoid production. Cytosolic
PLA2 preferably cleaves AA from phospholipids. Then, the cyclboxygenase (COX)
enzymes convert AA into the unstable endoperoxide intermediate PGG2 by a
cyclooxygenase reaction (oxygenation) and subsequently to PGH2 by a peroxidase
reaction (removal of 2e"). Prostaglandin H2 is next converted into prostanoids (PGD2,
PGE2, PGF2a, thromboxane A2, and PGI2) by specific isomerase enzymes (e.g. PGD
synthase, PGE synthase, PGF synthase, Tx synthase, PGI synthase; Flower and Vane,
1972; Smith and Lends,, 1972; Needleman et al., 1986; Smith et al., 1991). The ratelimiting step in prostaglandin biosynthesis is believed to be either the cleaving of AA
from the cell membrane or the conversion of AA to the PG intermediates (van der Bosch,
1980; Levy et al., 2000, respectively). This pathway is depicted in Figure 2.
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Figure 2.
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Alternatively, free AA can be converted into other eicosanoids such as
leukotrienes (LTs), lipoxins (LPXs) and hydroxyeicosatetraenoic acids (HETEs) by an
enzyme called 5-lipoxygenase (5-LO; McCracken, 2005). Unlike the COX enzymes, 5LO requires activation by Ca2+ and translocation to the cell membrane. Leukotrienes and
HETEs are involved in inflammation, vasoconstriction and blood flow associated with
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asthma and allergic rhinitis (Currie et al., 2005; Graeme et al., 2005; Miyata and Roman,
2005) whereas LPXs are anti-inflammatory compounds (Claria and Planaquama, 2005).

Cvclooxygenase-l:
Cyclooxygenase-1 (COX-1), also known as PGH2 synthase-1, is a 600-602 amino
acid enzyme (MW-70 kDa) that is glycosylated at Asn68, Asnl44, and Asn410, and is
involved in prostaglandin synthesis (Garavito and Mulichak, 2003). It was purified from
seminal vesicles of sheep (Hemler and Lands, 1976; Van der Ouderaa et al., 1977) and
cow (Miyamoto et al., 1976) and was later cloned from the same tissue (DeWitt and
Smith, 1988; Merlie et al., 1988). The COX-1 gene is 22 kb and is located on
chromosome 9 (Robertson, 1998). The mRNA transcript is 2.8-3 kb and is relatively
stable. The promoter region, which contains SPl-like elements, has low inducibility so
the enzyme is constitutively expressed in most cell types and tissues, e.g. smooth muscle,
fibroblasts, stomach, and kidney, but is expressed in relatively large amounts in
fibroblasts and endothelial cells (DeWitt et al., 1983; Funk et al., 1991; Kraemer et al.,
1992). It was shown through immunocytochemistry that COX-1 is associatedMth the'
membranes of the endoplasmic reticulum and nucleus, but not the plasma or
mitochondria of cultured fibroblasts (Rollins and Smith, 1980). Cyclooxygenase-1 plays
more of a "housekeeping" role because of its association with PGI2 and PGE2 production,
which are involved in vasodilation and maintaining gastric mucosa and kidney function
(Moncada et al., 1976; Whittle et al., 1978; Smith, 1992). The cyclooxygenase-1 protein
consists of 5 regions (Figure 3); (1) signal peptide, (2) dimerization domains, (3)
membrane binding domain, (4) catalytic domain and (5) membrane targeting sequence
21

(Picot et al., 1994; Simmons et al., 2004). The signal peptide (22-26 amino acids) resides
at the N-terminus and serves to direct the enzyme into the lumen of the endoplasmic
reticulum or nuclear membrane. Following this domain are 8 amino acids that are not
found in COX-2. The function of these residues is unknown. The dimerization domain,
also called the epidermal growth factor-like domain, is approximately 50 amino acids in
length and allows for dimerization with COX-1 but not COX-2. The homodimer is held
together by four disulfide bonds; three by the dimerization domains and one by the
catalytic domain. The membrane binding domain is composed of 50 amino acids that
form four helices whose surfaces are hydrophobic. These helices penetrate the
hydrophobic core of the lumen side of the endoplasmic reticulum/nuclear phospholipid
bilayer. As a result, the dimers float on the surface of the lumen. The catalytic domain
composes most of the enzyme (480 residues) and contains two active sites;
cyclooxygenase and peroxidase active sites. The cyclooxygenase active site is a long,
narrow, hydrophobic channel that contains tyrosine 385 which forms a tyrosyl radical.
This radical removes a hydrogen from carbon 13, of AA, creating an arachinonyl radical
' that can now be converted in PGG2 by an oxygenation reaction. This reaction is governed
by two other residues that reside in the channel: serine 530 and valine 349. The
peroxidase active site is represented by a shallow cleft in the active site. Here, heme is
bound to iron which is bound to His388 in sheep COX-1. A large portion of the heme is
exposed allowing for interaction with PGG2. Subsequently, PGG2 is converted into PGH2
by the peroxidase active site.
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Cyclooxygenase-2;
The COX-2 (PGH2 syfithase-2) gene was first isolated and cloned from chicken
embryo cells (Simmons et al., 1989; Robertson, 1998); It is 8 kb and is located on
chromosome 10 (Kulkarni et al., 2000). The mRNA transcript is 4-4.5 kb and is degraded
relatively quickly. The enzyme was purified by Sirois and Richards in 1992 from preovulatory rat follicles and is composed of 604 amino acids which yield a molecular
weight of approximately 72 kDa. Cyclooxygenase-2 share,s 63% amino acid homology
with COX-1 (Yokoyama and Tanabe, 1989; Kraemer et al., 1992; Garavito and
Mulichak, 2003) and has the same glycosylated residues as COX-1 with an additional one
at Asn588. Like COX-1, COX-2 is bound to the membranes of the nucleus and the
endoplasmic reticulum and is also involved in prostaglandin synthesis. Cyclooxygenase-2
comprises the same five regions as COX-1 (Figure 4) and functions insimilar ways. The
active site of COX-2 converts AA to PGG2 by oxygenation and subsequently to PGH2 by
23

peroxidation, which is a heme-dependent reaction. However, a substitution of Val523 in
COX-2 for Ile523 in COX-1 opens up a hydrophobic pocket in COX-2 that allows COX-.
2 selective drugs to bind (Kurumbail et al., 1996). While GOX-1 and -2 have the same
affinity for AA, the hydrophobic pocket in COX-2 allows for bulkier substrates such as
endocannabinoids to be converted to endocannabinoid-derived prostanoids (Kozak et al.,
2002, 2(303). Another distinct difference is that COX-2 is inducible whereas COX-1 is
not. The promotor region of the COX-2 gene contains a c AMP response element,
CREB/NF-IL-6 element and NFkB sites which are critical for maximum transcription of
COX-2 (Sirois and Richards, 1993; Crofford et al., 1997; Herschman et al., 1997;
Kulkarni et al.,\ 2000). Additionally, PPARy response elements, Ets sites and PEA sites
have been identified in the promoter region of the COX-2 gene; however, their function
remains unknown (Smith et al., 2000). Cyclooxygenase-2 is induced in fibroblasts by
growth factors (epidermal growth factor, platelet derived growth factor and transforming
growth factor /3), phorbol esters, interleukin-1 (IL-1); lipopolysaccharide (LPS) in
monocytes and macrophages, and tumor necrosis factor (TNF) in endothelial cells
(Lafyatis et al., 1989; Lin et al., 1989; Smith et al., 1994). Unlike COX-1, COX-2 is
inhibited by glucocorticoids such as dexamethasone. Because COX-2 is an inducible
enzyme, large concentrations of prostaglandins are produced leading to diseases
involving pain and inflammation (Dubois et al., 1998; Mollace et al., 2005). For example,
COX-2.is associated with pathological conditions such as arthritis and cancer. Individuals
with arthritis have increased COX-2 expression arid prostaglandin production (Andersori
et al., 1996). Human and animal colorectal tumors express high concentrations of COX-2
whereas normal intestinal mucosa does not (Kutchera et al, 1996). However,
'
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physiological events such as ovulation and luteolysis are also accompanied by an increase
in prostaglandins which is the result of CQX-2 induction (Richards et al., 1995).
Figure 4.

COX-2

Cyclooxygenase-3:
The COX-3 isoform (-65 kDa) is a COX-1 gene derivative isolated and
characterized by Chandrasekharan et al. (2002). It contains the same regions as COX-1
and -2 isozymes, but it retains intron 1 (Figure 5). Glycosylation by the endoplasmic
reticulum is essential for activation and is expressed predominantly in the brain. The
inhibition of COX-3, but not COX-1 or -2, by a therapeutic dose of acetaminophen,
phenacetin, antipyrine, and dipyrone (antipyretic and analgesic drugs) suggests that the
primary function of COX-3 is to induce pain and fever (Warner et al., 2004).
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Figure 5.
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COX Expression during the Estrous Cycle and Luteolysis:
Studying the expression of COX enzymes, especially COX-2, during luteolysis is
important because they are necessary for PG production. If COX expression within the
CL increases during luteolysis, not only will uterine PGF2a be exerting its effects on the
CL, but intraluteal PGF2« will be acting on the CL to cause its eventual demise. Several
in vivo studies have investigated the expression of luteal COX-2 expression during the
estrous cycle or in response to PGF2a. Expression of luteal COX-2 increases from day 717 during the bovine estrous cycle (Arosh et-al., 2004). Similar results in the cow were
observed by Hayashi et al. (2003). In another study, sheep were infused with 1 umol of
PGF2a through the ovarian artery on day 11 or 12 of the estrous cycle and corpora lutea,
were removed at 1, 4, 12 and 24 hours afterwards (Tsai and Wiltbank, 1997). Expression
of COX-2 mRNA increased at the 1 and 4 hour time points when compared to controls
before returning to basal concentrations. Levy et al. (2000) supported these findings. In
the pseudopregnant rabbit, a 200 ug i.m. infusion of the PGF2a analogue alfaprostol on
days 4 or 9 resulted in an increased expression of COX-2 mRNA 1.5-6 hours after
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treatment (Zerani et al., 2007). It is not surprising that COX-1 expression does not change
in response to PGF2a treatment because it is non-inducible (Arosh, 2004; Zerani et al.,
2007).
Administering a luteolytic dose of PGF2a may not mimic events associated with
the physiological onset of luteolysis in sheep. Therefore, Allen (UNH Master's Thesis)
and Ricketts (UNH Master's Thesis) used a model in which sheep received infusions of
PGF2a that mimic physiological conditions during the onset of luteolysis to determine the
expression of COX-1 and COX-2 in the CL. Following a single 1 hour infusion of PGF2a
(0.22 ug/kg/min), COX-2 protein increased 16 and 24 hours after treatment when
compared to untreated sheep (Allen, UNH Master's Thesis). This increase was
maintained 1,8, 16, and 24 hours following a second infusion of PGF2tt (0.22 ug/kg/min)
when compared to untreated sheep (Ricketts, UNH Master's Thesis). Cyclooxygenase-1
expression remained unchanged after the first and second infusions of PGF2a.

Prostaglandin F2„ as the Luteolytic Agent:
If pregnancy does not occur, the CL undergoes luteolysis, allowing for a new
cycle to begin. For a long time, it was unknown what factor(s) signal luteolysis; however,
several studies involving uterine effects on the ovary identified the hormone
prostaglandin F2« (PGF2a) as the signal. Early studies in the hysterectomized guinea pig
(Loeb, 1923, Denamur et al., 1966), sheep (Demers et al., 1972), cow (Demers et al.,
1972), and mare (Ginther, 1971) during the luteal phase extended the lifespan of the CL
that was equal to or longer than pregnancy. This strongly suggested that the luteolytic
agent was of uterine origin. To confirm this finding, autotransplant experiments in sheep
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were performed. One ovary of a sheep was removed from the abdominal cavity and
attached to the jugulo-carotid loop in the neck (Goding et al., 1967; McCracken and
Baird, 1969). As a result, the CL in the transplanted ovary remained for greater than 100
days. Conversely, if both the ovary and ipsilateral uterine horn are transplanted to the ;
neck, normal luteal regression occurs (McCracken et al., 1973). Collectively, these
experiments support the notion that the luteolytic agent is of uterine origin and that it acts
locally, not systemically.
Pharriss and Wyngarden (1969) suggested that PGF2a was the luteolytic agent in
mammals because it was abundant in the rat uterus. Prostaglandin F2a was later
determined to be the luteolytic agent in sheep (McCracken et al., 1972). Similarly, PGF2a
is the luteolytic agent in the cow (Nancarrow et al., 1973; Kindahl et al., 1976; Milvae
and Hansel, 1983a; Jarowszewski et al., 2003), the pig (Gleeson et al., 1974; Moeljono,
1976), and the guinea pig (Poyser, 1976). Furthermore,PGF2a is secreted from the uterus
in a pulsatile manner in ruminants (McCracken et al., 1973; Kindahl et al., 1976a;
Kindahl et al., 1976b; Kindahl et al., 1980; Kindahl et al., 1984), the sow (Kindahl et al.,
1981), and the guinea pig (Elger et al., 1994). In ewes, Zarco et al, (1988) determined that
multiple, sequential pulses of PGF2a are required for luteolysis. Specifically, eight onehour pulses of PGF2«, on average, are noted during the luteal phase in which the first one
starts on day 13 of the estrous cycle. The interval between the first two pulses is 16 hours(
while all intervals after that are 8 hours. Although eight pulses of PGF2a occur, 4-5 pulses
are usually adequate to induce full regression of the CL (McCracken et al., 1999;
Schramm et al., 1983).
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These pulses of uterine PGF2K in sheep act locally on the CL because a systemic
infusion of PGF2a (25 ug/hr) did not result in regression of the CL (McCracken, 1971).
The failure of systemic PGF 2a can be accounted for by a dilution effect and the fact that
>99% of PGF2a is readily metabolized by one passage through the lungs (Davis et al.,
1980). If PGF2a is metabolized by the lungs, then there must be another route that uterine
PGF2« travels to exert its effects on the ovary. Such a hypothesis was tested over a series
of experiments in sheep (McCracken et al., 1971; McCracken et al., 1972; McCracken et
al., ,1973). Given that the utero-ovarian vein and the ovarian artery are twisted around
each other, it was thought that substances secreted by the uterus could diffuse into the
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ovarian artery and act on the ovary. To test this hypothesis, [ H]PGF2a (0.1 /iCi/min) was
infused into the uterine vein for one hour. Afterwards, 1% of it was recovered in the .,
adjacent ovarian artery. Since each uterine horn releases 25 jUg/hour PGF2« into their
• r -

respective uterine veins (McCracken, 1972; Green et al., 1972), the same dose of PGF2a
was infused into the uterine vein in situ or was given systemically (control animals). As a
result, the in situ CLs underwent premature luteolysis whereas the systemic infusions did
not induce luteolysis. Collectively, these studies support the theory behind the counter- ,.
current transfer in which uterine PGF2Q. traveling through the utero-ovarian vein diffuses
into the ovarian artery where it can subsequently act on the CL to initiate luteolysis.
Although PGF2a is the central hormone that initiates luteolysis, it is important to
review some of the factors that trigger its release from the uterus as well as within the
CL. To explain the release of PGF2« from the uterus, experiments based on the Ferguson
^reflex (Ferguson, 1941), the mechanical stimulation of the female reproductive tract to
stimulate neurohypophysial release of oxytocin, were pursued. Roberts and Share (1968,
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1970) demonstrated that vaginal distension in sheep and goats causes an increase in blood
oxytocin concentrations while it was shown that mechanical stimulation of the uterus
resulted in secretion of PGF2« early and late in the sheep estrous cycle (Wilson et al., '
1974). This hypothesis was strengthened by the work of Armstrong and Hansel (1959) in
which they found that exogenous oxytocin resulted in premature luteolysis in cows.
However, the direct link between oxytocin and uterine PGF2« production was not shown
until McCracken (1980) demonstrated that a physiological dose of oxytocin (200 pg/min)
infused into the uterine artery of sheep for 10 minutes on different days of the ovine
estrous cycle (days 3, 8, 13 arid 14) resulted in an increase in PGF2a secretion on days 3
and 14. The lack of PGF2a increase on days 8 and 13 can be explained by the decrease in
oxytocin receptors on the endometrium and myometrium of the uterus during those days
of the estrous cycle. Regulation of oxytocin receptors on the uterus is controlled primarily
by E2 and P4. Estradiol enhances expression of oxytocin receptors in the sheep (Sharma
and Fitzpatrick, 1974) and rat (Soloff, 1975) uterus; however, this effect was blocked in
sheep by the addition of P4.
In addition to being secreted by the uterus, PGF2a is produced by the CL in
several species. Prostaglandin F2« is produced by corpora lutea of women (Shutt et al.,
1976; Swanston et al., 1977; Patwardhan and Lanthier, 1980), sows (Guthrie et al., 1978),
ewes (Rexroad and Guthrie, 1979; Tsai and Wiltbank, 1997), cows (Milvae and Hansel,
1983b; Pate, 1988), and rodents (Olofsson et al, 1992). Guthrie and Rexroad (1980a)
showed that intraluteal PGF2a increases from mid (days 8, 12, and 14) to late (days 16
and 18) luteal phase in pigs. Similarly, in the cow, DelVecchio et al. (1995) showed that
cells from late luteal stage CLs (days 17-18) produced more PGF2athan cells from mid
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luteal stage CLs (days 10-12). In the pseudopregnant rabbit, a 200 ug i.m. infusion of a
PGF2a analogue induced an increase in PGF2„ production by luteal cells (Zerani et al.,
2007). Tsai and Wiltbank (1997) found that ovine luteal cells in culture increased COX-2
production after addition of PGF2a, which increases PGF2a production by the CL. In
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addition, Milvae (2000) suggests that in ruminants, endothelin-1 (ET-1) increases luteal
PGF2a. However, Milvae and Hansel (1983b) showed that CLs from day 5 of the bovine
cycle produced more PGF 2a than day 10, 15, and 18 CLs. To explain these high
concentrations of PGF2a early in the luteal phase without regression of the CL, it has been
suggested that the young CL is not responsive^to PGF2a. Gadsby et al. (1990) showed that
day 6-8 CL had less high affinity binding sites for PGF2« than the day 12, 13, 14, 16, and
17 porcine CL, suggesting that as the CL ages, it becomes more sensitive to PGF2a.
Collectively, these studies indicate that uterine as well as intraluteal PGF2« production
contribute to the eventual demise of the CL.
Matrix MetaUoproteinases:
Matrix metalloproteinases (MMPs) are a family of divalent cation-dependent
proteases that break down the components of extracellular matrix (ECM) to aid in tissue
remodeling (Roy, 2006). The components of the ECM include proteins such as collagen,
gelatin, fibronectin, nidogen, laminan, aggrecan, and elastin (Table 1). Physiological
events within the body that require tissue remodeling include embryonic development,
morphogenesis, angiogenesis, reproduction, and tissue reabsorption. Pathological events
that require this process include tumorigenesis/metastasis and arthritis (Vincenti et al.,
1994; Nagase and Woessner, 1999; Roy et al, 2006). Currently, 24 MMPs have been
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identified, 23 of which are present in humans, and are categorized into the following
families: collagenases, gelatinases, stromelysins, membrane type-MMPs (MT-MMPs),
matrilysins, and other MMPs (Visse and Hideaki, 2003; Clark et al, 2008). These
families are defined by the substrates (ECM components) they bind and degrade.
The basic structure of MMPs consists of five domains (Figure 6; Woessner,
1991; Visse Nagase, 2003; Roy et al., 2006). The first is a signal peptide (19-29 amino
acids) that targets the enzyme for secretion by the cell by sending it to the rough
endoplasmic reticulum during synthesis. The second is the propeptide domain (80 amino
acids) which maintains the latent form of the enzyme. The third is the catalytic domain
(170 amino acids) which contains a highly conserved Zn binding region
(HExGHxxGxxHS/T) and is the site of enzyme activity. The zinc ion is bound to three
residues from the catalytic domain and one (cysteine) from the propeptide (Figure 7;
Vallee and Auld, 1990b). The fourth is the hemopexin domain (210 amino acids) which
determines substrate specificity. This domain is required by MMPs for them to cleave
triple helical collagens (Bode, 1995) and is an essential structure involved in the
activation of proMMP-2 by MT-MMP (Murphy et al., 1992). The fifth is the .hinge region
which presents the hemopexin domain, with bound substrate, to the catalytic domain for
degradation.
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In order to understand how these enzymes function, it is necessary to discuss their
activation process. One notable characteristic of MMPs is that they are synthesized and
secreted as latent enzymes and are activated extracellularly. In the latent form, the
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propeptide domain forms a cysteine-zinc bridge with the catalytic domain, blocking
enzyme activity (Woessner, 1991). Upon secretion by the cell, the enzyme can be
activated by trypsin, plasmin, kallikrein, and MMPs (Figure 7; Murphy et al, 1991).
Plasmin is a serine protease secreted as plasminogen from the brain and liver and is
activated by tissue plasminogen activator (tPA) or urokinase plasminogen activator (uPA;
Raum et al.,-1980; Mignatti et al., 1986; Alexander and Werb, 1992; Sappino et al.,
1993). These activators break the cysteine-zinc bridge and cleave the propeptide domain
exposing the zinc core within the catalytic domain (Van Wart and Birkadel-Hansen,
1990). This allows water to bind to zinc, a crucial ligand in activation of this enzyme,
resulting in degradation of the ECM by protein hydrolysis (Vallee and Auld, 1990a;
Vallee and Auld, 1990b). Furthermore, MMPs can degrade their own propeptide region
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by autocatalytic cleavage. In other words, once an MMP has been activated, it can
continue to cleave the remainder of the propeptide. Depending on how much of the
propeptide is cleaved off, an individual MMP (e.g. active MMP-.2) can have various
molecular weight forms.
Matrix metalloproteinase-1 was the first member of this enzyme family to be
isolated from tadpole tail, gill, and gut during natural and hormone-induced
metamorphosis (Gross and Lapiere, 1962). It was subsequently isolated from rat bone
(Walker et al., 1964). Since then, other members have been characterized giving rise to
the six families previously mentioned. The gelatinase family comprises MMP-2 and
MMP-9 and will be the focus of the next sections.
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Matrix metalIoproteinase-2:
Matrix metalloproteinase-2 (Gelatinase A) was first found to be present in
medium of cultured explants of a mouse tumor (Liotta et al., 1979). It was partially
characterized by Liotta et al. (1981) and then purified and characterized by Collier et al.
(1988). It has subsequently been found in various tissues and cell types such as bovine
. . .
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and sheep corpora lutea (Goldberg etal., 1996; Towle eft al., 2002, respectively), follicle
(Curry et al., 2001), uterus (Bany et al., 2000), endothelial cells (Hanemaaijer et al.,
1993), rat granulation tissue (Nakagawa et al., 1987), human skin (Seltzer et al., 1981),
synovial fluid (Koolwijk et al., 1995), tumors (Iurlaro et al., 1999), bone (Kusano et al.,
1999), fibroblasts (Saed et al., 2000) and other tissues that undergo structural remodeling.
The human MMP-2 gene (27 kb), found on chromosome 16 (Huthtala et a al., 1990b,
Huhtala et al., 1991), consists of 2733 nucleotides which yield a protein of 621 amino
acids: The promoter region does not contain a TATA or GAAT box; however, it does,
contain a GGGCGG consensus sequence that binds the transcription factor SP-1 (Huhtala
et al., 1990a). It also contains a CCCCAGGC (CG box) consensus sequence and is a
potential binding site for activator prOtein-2 (AP-2), The MMP-1 and -3 promoters
contain the 12-O-tetradecanoylphorbol 13-acetate (TPA) response element sequence
(TGAGTCAG) while it is not present in MMP-2. This is an interesting finding because
Salo et al. (1985) showed that TPA increases MMP-2 activity and mRNA concentrations.
However, the effects of TPA on MMP-2 remain uncertain because Collier et al. (1988)
showed that it has no influence on MMP-2 production. Matrix metalloproteinase-2 is
constitutively expressed in most cell types (Salo et al., 1985, Templetone et al., 1990;
Huhtala et al., 1991; Yeow et al., 2001) and is only moderately induced (transforming
growth factor-/3; TGF-/3) or repressed 2-4 fold, suggesting that it is regulated primarily by
their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs; Huhtala et
al., 1991; Overall et al., 1991; Salo et al., 1991). Matrix metalloproteinase-2 contains the
previously mentioned five domains in addition to another one called fibronectin type II
repeat (Figure 6; Collier et al., 1988), a region specific to gelatinases that binds collagens
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and gelatins (Allan et al, 1995; Steffensen et al., 1995). This region is encoded by three
additional exons of the MMP-2 gene that are lacking in MMP-1 and -3 (Huhtala et al.,
1991). The bovine MMP-2 gene consists of 2350 base pairs and shares 94.7%, 94.1%,
93.5%, 93%, and 95.9% homology to that of human, rat, mouse, rabbit and pig,
respectively (Zhang et al., 2005). The latent and active forms of this enzyme have
molecular weights of approximately 72 kDa and 66 kDa, respectively.

Matrix metalloproteinase-9:
Matrix metalloproteinase-9 (Gelatinase B) was first found to be present in human
leukocytes (Sopata and Dancewicz, 1974). It was later purified and characterized by
Wilhelm et al. (1989) and Morodomi et al. (1992). The human MMP-9 gene (7.7 kb),
found on chromosome 2.0, consists of 2334 nucleotides yielding a protein of 707 amino
acids (Wilhelm et al., 1989; Collier et al, 1991; Huhtala et al, 1991). It has subsequently
been found in a variety of tissues such as bovine and sheep corpora lutea (Goldberg et al.,
1996; Towle et al., 2002, respectively), follicle (Curry et al., 2001), uterus (Bany et al.,
2000), endothelial cells (Hanemaaijer et al., 1993), synovial fluid (Roolwijk et al., 1995),
tumors (Iurlaro et al., 1999), bone (Kusano et al., 1999), fibroblasts (Saed et al., 2000)
and other tissues that undergo structural remodeling. The preferred substrates for MMP-2
and -9 are collagen IV and gelatin, but they also degrade elastin and fibrillin, A list of
MMPs and their substrates is outlined in Table 1. Similar to MMP-2, the MMP-9
promoter lacks TATA and CAAT boxes (Huhtala et al., 1991). However, the MMP-9
promoter contains a TATA-like sequence (TTAAA) whereas MMP-2 does not. It also
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contains the CG box found in MMP-2 that allows SP-1 to bind. Unlike MMP-2, the
MMP-9 promoter contains 2 sequences that serve as activator protein-1 (AP-1) binding
sites, which is stimulated by TPA. In addition, it contains a TPA response element, which
is lacking in MMP-2. Transcription of MMP-9 is increased up to 8-fold by TGF-/3 (Salo
et al., 1991; Overall et al., 1991). The latent andactive forms of this enzyme have
molecular weights of approximately 92 kDa and 84 kDa, respectively. Matrix
metalloproteinase-9 is composed of the same domains as MMP-2, but it also has a 54
residue sequence located adjacent to the carboxyl-terminal side of the zinc-binding
domain (Wilhelm et al., 1989; Huhtala et al., 1991). This sequence shares 30-50%
homology to part of the a2(V) chain in collagen. Wilhelm et al. (1989) suggested that it is
the result of genetic recombination of the functional domains between MMP-9 and
collagen.

Table 1.
Matrix Metalloproteinase Families
Family

MMP
number

Molecular
mass (kDa)

L
Collagenases ! MMP-1

: 52

A

L = Latent, A = Active
Chromosomal location

Human

; 42 : Ilq22-q23

38

Prototypical ECM
substrates

Mouse
9 (A1-A2) Collagen I, II, III,
VII, VIII, X, XI;
gelatin,
entactin/nidogen,
fibronectin, laminin,

A

Family

MMP
number

Molecular
mass (kDa)

L

A

Chromosomal location

•!

Human

Mouse
perlecan vitronectin,
aggrecan

V

MMP-8

85

64

MMP-13

52

•. 42

MMP-2

72

MMP-9

Stromelysins ; MMP-3

Ilq21-q22 j 9p24.1

Collagen I, II, III;
gelatin, entactin,
aggrecan, tenascin

llq22.3

9(A1-A2)

Collagen I, II, III, VI,
IX, X, XIV; gelatin,
fibronectin,
vitronectin, aggrecan,
osteonectin

66

16ql3

8 (42.9)

Collagen I, III, IV, V,
VII, X, XI; gelatin,
fibrillin, fibronectin,
elastin, vitronectin,
aggrecan,
osteonectin, tenascin,
laminin-5

92

84

20qll.2ql3.1

2(H1-H2)

Collagen IV, V, XI,
XIV; gelatin, decorin,
elastin, fibrillin,
laminin, vitronectin,
aggrecan ,

57

45

llq23

9(1.0)

Collagen III, IV, V,
VII, IX, X, XI;
gelatin, decorin,
elastin,
entactin/nidogen,
fibrillin, fibronectin,

--'

Gelatinases

Prototypical ECM
substrates
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Family

•

MMP
number

Molecular
mass (kDa)

Chromosomal location

L

Human

A

Mouse

)

MT-MMPs

laminin, vitronectin,
aggrecan, osteonectin

MMP-10

54

44

llq22.3q23

MMP-14

66

54

14qll-ql2 i 14(12.5)

Collagen I, II, III;
gelatin, fibronectin,
vitronectin,, aggrecan

MMP-15

72

• 60

16ql3-q21

8(45.5)

Proteoglycan

MMP-16

64" : 53 i 8q21

4(3.6)

Collagen III,
fibronectin

MMP-17

57

53

12q24,3

5(1.0)

Gelatin,
fibrin/iibrinogen

MMP-24

73 .

62

20ql 1.2ql2

2(1.0)

Fibronectin,
proteoglycans, gelatin

MMP-25

63

62

16pl3.3

. \

Collagen IV, gelatin,
lamihin-1,
fibronectin,
proteoglycans,
fibrin/fibrinogen

MMP-7

28

19

Ilq21-q22

9(1.0)

Collagen I, IV,
decorin, elastin,
fibrillin, fibronectin,

1

Matrilysins

Prototypical ECM
substrates

40

9p24.1 .

Collagen III, IV, V;
gelatin, elastin,
fibronectin, aggrecan

Family

MMP
number

Molecular
mass (kDa)

Chromosomal location

L

Human

A

Mouse
laminin, vitronectin,
aggrecan, osteonectin

. -

Other MMPs

Prototypical ECM
substrates

MMP-26

29

19

l i p 15

MMP-11

64

46

22qll.2

MMP-12

54

22

llq22.2q22.3

MMP-19

54

45 : 12ql4

10(71.0)

CollagenTV, gelatin,
laminin, fibronectin,
fibrin/fibrinogen

MMP-20

54

22

llq22.3

9(1.0)

Amelogenin,
aggrecan

MMP-23

44

31

lp36.3

Collagen IV, gelatin,
fibronectin,
fibrin/iibrinogen
10 (40.9)

j 9(1.0)

Fibronectin, laminin,
aggrecan
Fibronectin, elastin,
laminin,
proteoglycan,
fibrin/fibrinogen

Gelatin

Adapted from Roy et al. (2006).

Tissue Inhibitors of Metalloproteinases:
Matrix metalloproteinases are regulated at several levels including gene
activation, transcription, mRNA stability, translation and secretion of latent proenzymes,
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binding of proenzymes to cell membranes, proenzyme activation, inactivation by
endogenous inhibitors, and degradation of the active site. Two endogenous inhibitors are
a^macroglobulin which is found in plasma, and tissue inhibitors of metalloproteinases
(TIMPs) which are typically associated with the ECM (Birkedal-Hansen et al., 1993;
Stetler-Stephenson et al., 1993; Baker et al., 2002). Currently, four members of the TIMP
family have been identified in vertebrates; TIMP-1 (Sellers et al, 1977; Murphy et al.,
1981; Carmichael et al., 1986), TIMP-2 (Stetler-Stevenson et al., 1989), TIMP-3 (Yang
and Hawkes, 1992), and TEVIP-4 (Greene et al., 1996). All TIMPs inhibit all MMPs with
the exception that TIMP-l can not inhibit MMP-14, -16, or -24 (Visse and Nagase,
2003). They form a 1:1 complex through reversible non-covalent binding with active and
less commonly, latent forms of MMPs resulting in inhibition. A balance of MMPs and
TIMPs maintains the integrity of the ECM. However, if MMP concentrations exceed
TIMP concentrations for example, the result is an increase in net proteolytic activity,
allowing for cell migration, angiogenesis, and tissue remodeling. Understanding the
structure and function of TIMPs and how they interact with MMPs will give us a better
idea of how the ECM remodeling is regulated. Due to the relationship between TIMP-l
and MMP-9 and TIMP-2 and MMP-2, TEVIP-l and -2 will be emphasized.

Tissue Inhibitor of Metalloproteinase-l:
Tissue inhibitor of metalloproteinase-l is an approximately 29 kDa glycoprotein
first described in rabbit bone (Sellers et al., 1977), and was subsequently isolated and
characterized (Murphy et al., 1981). It was then cloned from normal human fibroblasts by
Docherty et al. (1985) and Carmichael et al. (1986). The human TIMP-l gene consists of
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811 nucleotides giving rise to a protein of 206 amino acids. The ovine gene consists of
887 nucleotides yielding a 207 amino acid protein (Smith et al., 1994). The primary
structure of ovine TEV1P-1 is 95%, 86%, and 77% homologous to bovine, human, and
mouse, respectively. The first 23 amino acids from the N-terminus serve as a signal
peptide and are cleaved off upon secretion. The 3-dimensional structure contains six
disulfide bonds which form six loops making it highly stable (Figure 8; Williamson et
al., 1990). It preferentially binds to MMP-3, active MMP-1, and both active and latent
forms of MMP-9 (Welgus et al., 1983; Welgus et al., 1985; Wilhelm et al., 1989). The
inhibitory action of TEMP-1 resides in the three N-terminal loops which bind to the active
site of an MMP (Woessner and Nagase, 2000). Inhibitors of TIMP-1 include serine
proteinases such as trypsin, chymotrypsin, and elastase (Okada et al., 1988). Tissue
inhibitor of metalloproteinase-1 is found in aorta, gingival, dental pulp, cartilage,
embryonic bone, tendon, synovium, uterus, corpus luteum, follicles, fibroblasts, epithelial
^

cells, endothelial cells, osteoblasts, chondrocytes, smooth muscle, platelets, monocytes/
macrophages, and tumor cells (Takahashi et al., 1993; Hayakawa,vl994; Smith et al.,
1994; Pitzel et al., 2000; Goldman and Shalev, 2004; Lind et al., 2006; Bogusiewicz et
al., 2007; Skrzypczak et al, 2007).
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Figure 8.

Hayakawa(1994)

Tissue Inhibitor of Metalloproteinase-2;
Tissue inhibitor of metalloproteinase-2 is an approximately 21 kDa nonglycosylated protein (Stetler-Stevenson et al., 1989). The human gene consists of 1062
nucleotides which are translated into a 201 amino acid protein (Stetler-Stevenson et al.,
1990). Sheep mRNA for TFMP-2 was identified in ovine follicles and corpora lutea by
Smith et al. (1995). The primary structure of TIMP-2 has also been sequenced in calf
(Boone et al., 1990) and mouse (Shimizu et al., 1992). Human and mouse TIMP-2
sequences share 97% homology. Tissue inhibitor of metalloproteinase-1 and -2 share
43% homology so it is not surprising that TIMP-2 is composed of 201 amino acids, of
which the first 24 from the N-terminus serve as a signal sequence (Stetler-Stevenson et

al., 1989). Similar to TIMP-1, the 3-dimensional structure of TMP-2 contains six
disulfide bonds which form six loops (Figure 9); the three N-terminal loops binding to
the active site of MMPs. Although TIMP-2 binds all MMPs, it preferentially binds to the
active and latent forms of MMP-2 (Howard et al., 1991). It has been identified in rabbit
brain capillary endothelial cells (Herron et al., 1986), bovine aortic endothelial cells (De
Clerck et al, 1989), bone marrow cells (Zdzisinska et al., 2008), tumors (Xu et al., 2002),
sheep CL (Towle et al., 2002), cow CL (Goldberg et al., 1996; Zhang et al., 2003), uterus
(Zhang and Salamonsen, 1997), ovarian follicle (Bakke et al., 2002), skeletal muscle
(Singh et al., 2000), Leydig cells (Blavier and DeClerck., 1997), placenta (Marzusch et
al., 1996), and brain (Giraudon et al., 1995).
Figure 9.

Hayakawa(1994)
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Other actions of TIMPs:
Although the primary function of TIMPs is to inhibit MMPs, a function unique to
TIMP-2 actually aids in the activation of proMMP-2. This event includes the formation
of a complex between proMMP-2, MT-1MMP, and TIMP-2 on the cell surface.
Membrane-type-2, and -3 also aid in the activation of proMMP-2, but the complex
involving MT-MMP1 has been studied most extensively (Overall and Sodek, 1990; Sato
et al., 1994; Butler et al., 1997; Takino et al., 1995). Butler et al. (1998) demonstrated
that addition of MT-1MMP and TIMP-2 increased proMMP-2 activation; however, an
excess of TIMP-2 inhibited activation of proMMP-2. Furthermore, TIMP-2 lacking the
C-terminal domain did not enhance activation of proMMP-2. Therefore, Butler et al.
(1998) proposed that TIMP-2 and MT.l-MMP form a complex that acts as a receptor for
proMMP-2. When proMMP-2 binds to this "receptor", free/active MT1-MMP activates
proMMP-2. In this three-way interaction, the N-terminus of TIMP-2 bind to the active
site of MT1-MMP while its C-terminus binds to the hemopexin domain of proMMP-2
resulting in proMMP-2 activation by free/active MT1-MMP (Strongin et al., 1995).
Tissue inhibitor of metalloproteinase-1 may have a role in regulating the
activation of proMMP-9. As proMMP-9 is secreted by cells, it can form a complex with
MMP-1 which results in its activation by MMP-3 yielding an 82 kDa protein (Goldberg
et al., 1992; Ogata eta al., 1992; O'Connell et al., 1994). However, if TIMP-1 binds to
proMMP-9, the complex between proMMP-9 and MMP-1 can not occur and activation is
prevented.
An additional role of TIMP-1 within the CL may be to regulate steroidogenesis.
Boujrad et al. (1995) found that a 70 kDa complex consisting of TEMP-1 and cathepsin L
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activates steroidogenesis. Furthermore, Nothnick (2003) showed that serum P4
concentration was lower in TIMP-1 null mice than wild type.

MMP and TIMP Expression during the Estrous Cycle and Luteolysis:
In order for luteolysis to occur, tissue remodeling is essential. The^mRNA and
protein expression of MMPs and TMPs throughout the estrous cycle, along with their
regulation by PGF2a, in various species, have been reported. Xinlei et al. (2006) showed
an increase in staining for MMP-2 and -9 in the late luteal stage (day 15) in rhesus
mbnkey corpora lutea when compared to the early (day 5) and mid (day 10) luteal stages.
Also, mRNA for MMP-2 and -9 were assessed using in situ hybridization and MMP-2
mRNA expression matched the protein profile from the tissue staining; however, MMP-9
mRNA was too low to be detected. Similar results were reported in other species (Liu K
et al., 1999; Pitzel et al., 2000; Young et al., 2002; Kliem et al., 2007). However, Li et al.
(2002) showed that MMP-2 protein expression is undetectable on day 1 postpartum in the
rat. In tne cow, there was no difference in MMP-2 mRNA or latent MMP-2 between
early (day 4), mid (day 10), and late (day 16) cycle CLs (Zhang et al., 2005). Goldberg et
al. (1996) found that MMP-2 protein does not change throughout the bovine estrous
cycle. However, they found that proMMP-9 is highly expressed on day 4 of the cycle, but
decreases on days 8,10,12,14 and 16. In sheep CL, MMP-2 mRNA and activity was
highest on day 10 of the estrous cycle, whereas MMP-9 mRNA was undetectable (Ricke
et al., 2002).
Xinlei et al. (2006) assessed TIMP-1, -2 mRNA using in situ hybridization in the
rhesus monkey. The TIMP-1 mRNA expression decreased from day 5 to 15 while TIMP47

2 mRNA expression increased during the same time period. Similar results were found by
Inderdeo et al. (1996) and Young et al. (2002). However, Smith et al. (1995)
demonstrated that TIMP-2 mRNA concentrations decrease from early luteal phase (days
3-7) to late luteal phase (day 16) in corpora lutea of sheep. Expression of TEVIP-l and
TIMP-2 mRNA during early, mid and late pseudopregnancy were determined in the rat
(Nothnick et'al., 1995). While TIMP-2 remained unchanged, TIMP-1 expression
decreased to almost 0 % from early to mid stage pseudopregnancy. In the late stage of
pseudopregnancy (which is associated with CL regression), it increased to about 50% of
the expression seen in the early stage. In contrast, gene expression of TIMP-1 and -2 in
pig CL is high in the early luteal phase (days 6-8) and increases by the late luteal phase
(days 13-15; Pitzel et al., 2000). In the cow, TIMP-1 mRNA and protein decreased from
early (day 4) and mid (days 10-12) cycle CL to late (day 16) cycle CLs (Zhang etal.,
2003). In contrast, TIMP-2 mRNA and protein increased from early cycle CLs to mid
and late cycle CLs. Kliem et al. (2007) showed that TEVIP-1 mRNA from bovine follicles
increased in CL during the luteal phase (days 0-12).
Multiple factors such as PGF2a, endothelin-1 (He et al., 2007), nitric oxide (Nee et
- al., 2008), and cytokines (Nee et al., 2007) are known to regulate MMPs and TIMPs.

r

Since the focus of the present study is to determine the effects of physiological pulses of
PGF2a on MMPs and TIMPs, this aspect of PGF2a action will be reviewed. Kliem et al.
(2007) reported that MMP-2 mRNA expression in the cow was up-regulated 24 hours
after a luteolytic dose (500 ug i.m.) of PGF2tt and continued to increase through 64 hours.
On the other hand, MMP-9 mRNA expression increased 12-64 hours after PGF2a
treatment. Liu et al. (1999) profiled MMP-2 mRNA expression during the formation and
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regression of the CL in the pseudopregnant rat. They found that MMP-2 was expressed
in the CL on day 1 of pseudopregnaney and drastically decreased on day 7. A single 5 ug
s.c. injection of cloprostenol, a stable PGF2a analogue, was given on day 8 to initiate
regression of the CL and the low MMP-2 expression found in day 7 CL was maintained
in day 10,13,16, and 19 CLs. However, Endo et al. (1993) concluded that both the active
and latent forms of MMP-2 increased during structural luteolysis in the rat. Similarly, in
rats injected with GnRH, which is known to induce luteolysis, MMP-2 expression
increases during structural regression of the CL (Goto et al., 1999). In sheep, MMP-2
mRNA does not change in response to PGF2a treatment (15 mg i.m.), whereas MMP-9
mRNA was undetectable (Ricke et al., 2002).
In the cow, TEMP-1 and -2 mRNA expression decreased 12 hours and 12,48, and
64 hours, respectively, after PGF2« treatment (500 ug i.m.; Kliem et al., 2007). Similar
results were observed by Mclntush and Smith (1997) and Ricke et al. (2002) in sheep. In
contrast, Juengel et al. (1994) reported luteal TIMP-1 and -2 mRNA expression in the
cow CL increased eight hours after PGF2« treatment. It then increased 4 and 6 hours after
treatment when compared to controls. Although TIMP-2 mRNA was detected, it did not
change. Similarly, in the rat, TIMP-1 mRNA is present in the forming and regressing CL,
but not the functional CL, after a single 5ug (s.c.) injection of cloprostenol on day 8 of
pseudopregnaney (Liu et al., 1999).
, The single systemic infusions of PGF201 administered to animals in some of the
aforementioned studies are given in relatively high concentrations. However, natural
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luteolysis is driven by multiple pulses of PGF20 that are relatively lower in concentration.
Thus, we wanted to determine whether the expression of MMPs and TIMPs in response
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to a single luteolytic dose of PGF2a were different from the response to physiological
infusions of PGF2a- Therefore, Towle et'al. (2002) and Ricketts (UNH Master's Thesis)
used a model in which sheep received one or two infusions of PGF2a, respectively, that
mimic physiological conditions during the onset of luteolysis. Tissue inhibitor of
metalloproteinase-1 protein levels decreased by 55% one and eight hours following a
single one-hr infusion of PGF20: (-0.22 ug/kg/min) when compared to controls. Tissue
inhibitor of metalloproteinase-2 decreased 1, 8, and 24 hours by 80%, 80%, and 70%,
respectively, after the infusion when compared to controls. Meanwhile, active MMP-2
increased by 165% at the 8 hour time point while active MMP-9 remained unchanged.
Similarly, TIMP-1 protein decreased by 60% one hour following two one-hour infusions
of PGF2« (-.22 ug/kg/min) and increased to 120% 24 hours after the infusion. In addition,
TFMP-2 decreased by 80% one hour after the infusions and remained low through 24
hours. Active MMP-2 increased to 120% one hour following the second infusion while
latent MMP-2 and active MMP-9 remained unchanged throughout 24 hours after the
second infusion.
It is clear that MMPs and TBVIPs are involved in the structural regression of the
CL in several species. However, luteolysis also involves the functional demise of the CL,
which encompasses a decline in P4 production. Progesterone production is dependent, in
part, on the steroidogenic acute regulatory (StAR) protein. Therefore, the ensuing
discussion is a review of StAR and P4 in the CL.
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General Characteristics of the Steroidogenic Acute Regulatory (StAR) Protein:
\

The steroidogenic acute regulatory (StAR) protein is an approximately 30 kDa

phosphoprotein (259-287 amino acids) associated with mitochondria (Clark et al., 1994).
It is processed from two precursor proteins (32 kDa and 37 kDa) and is a key component
in steroid biosynthesis (Krueger and Orme-Johnson, 1983; Pon et al., 1986; Pon and
Orme-Johnson 1988; Stocco and Kilgore, 1988; Epstein and Orme-Johnson, 1991; Stocco
and Sodeman, 1991). In 1994, it was sequenced and cloned in MA-10 mouse Leydig
tumor cells-by Clark et al. (1994). The human StAR gene (855 nucleotides) resides on
chromosome 13 and is predominantly found as a 1.6 kb transcript, but has also been
described as a 4.4 kb and 7.5 kb transcript (Sugawara et al., 1995). The cDNA used to
probe for StAR mRNA in this experiment was about 1.6 kb which explains why the 1.6
kb transcript was most abundant. The 4.4 kb and 7.5 kb transcripts most likely represent
full length transcripts of StAR. The StAR gene was later cloned from rat (Sandhoff et al.,
1998), cow (Hartung et al., 1995), pig (Pilon et al., 1997), mare (Kerban et al., 1999), and
hamster (Fleury et al., 1996). Interestingly, the StAR and TIMP-1 genes share a
homology sequence of 124 bases in a noncoding region, suggesting that these two
proteins may be regulated similarly (Hartung et al., 1995). Naturally occurring mutations
of the StAR gene in patients with congenital lipoid adrenal hyperplasia result in severely
reduced adrenal and gonadal steroid synthesis (Lin et al., 1995). Once translated, the ,
mRNA yields a 37 kDa protein that is phosphorylated at residues 194 and 195 in mouse
and human, respectively; an important characteristic for the function of StAR (Arkane et
al, 1997). The StAR protein is selectively expressed in all steroidogenic tissues, such as
adrenal fasiculata, corpus luteum, gonads, adrenal glomerulosa cells, and the placenta of
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cows, pigs, and rodents (Strauss et al., 1996). It is also expressed in the brain, nerves, and
kidney (Carroll et al., 1 9 % Clark et al, 1995).

StAR Protein Structure and Function:
"

-

V

Once the 37 kDa form of StAR protein is synthesized and phosphorylated, it
transports cholesterol from the outer mitochondrial membrane to the inner mitochondrial
membrane, the rate-limiting step in steroid biosynthesis. During this event, the 37 kDa
form of StAR is cleaved to yield the 32 kDa and ultimately the 30 kDa form and becomes
inactive while cholesterol is converted into pregnenolone by the side chain cleavage
enzyme (P450scc; Farkash et ai., 1986; Clark et al., 1994; Pescador 1996; Paz et al.,
2002). Understanding how StAR functions has come from studying its protein structure.
The N-terminus of the 37 kDa form contains a mitochondrial targeting sequence, which
directs it to the mitochondria (Figure 10). Amino acids 63-193 serve as a protease
resistant region (Song et al., 2001). The C-terminus contains a START (StAR-related
lipid transfer) domain consisting of 210 amino acids and appears to be the key functional
part of this protein because steroidogenesis is inhibited in cells in which the C-terminal
region is truncated by 28 amino acids (Arkane et al., 1996; Wang et al., 1998). The
START domain has also been found in several other proteins involved in steroidogenesis
such as one found in the lymph node called metastatic lymph node 64 (MLN64; Watari et
al., 1997; Kallen et al., 1998; Potter and Aravind, 1999; Soccio and Breslow, 2003). The
function of MLN64 is to transport cholesterol out of vesicles formed by endocytosis of
LDL (Strauss et al., 2003). The START domain of-MLN 64 shares 35% homology with
the one in StAR and allows both proteins to bind cholesterol in a 1:1 ratio (Tsujishita and
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Hurley, 2000). The StAR protein is typically found in gonads while MLN 64 is found in
the brain and placenta; however, the START domain of both proteins contains a
hydrophobic channel in which one molecule of cholesterol binds. Furthermore, mutant
forms of MLN64 which contain only the START domain binds cholesterol and increases
steroidogenesis by P450scc (Watari et al., 1997; Tsujishita and Hurley, 2000).

Figure 10.
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Signal Transduction Pathways of StAR:
Steroidogenesis is regulated primarily by cyclic adenosine monophosphatedependent (cAMP-dependent), and to a lesser degree, by cAMP-independent pathways
(Stocco et al., 2005). In the cAMP-dependent pathway, LH or human chorionic
gonadotropin (hCG) binds to a 7-transmembfane, G protein coupled receptor of a
steroidogenic cell and activates adenylate cyclase, the enzyme that converts adenosine
triphosphate (ATP) to cAMP (Oon and Johnson, 2000). Cyclic AMP then'phosphorylates
protein kinase A (PICA), which subsequently initiates transcription and translation of
StAR. In addition, PKA phosphorylates StAR protein that is already translated (Stocco
and Kilgore, 1988; Clark et al., 1994; Arkane et al., 1997). The increased cAMP that
•

•
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results from activation of this pathway also induces arachidonic acid (AA) release which,
in turn, increases intracellular Ca2+ (Alila et al., 1990; Jamaluddin et.al., 1992; Kumar et
al., 1994). Inhibition of AA synthesis reduces P4 production, StAR promoter activity,
StAR mRNA, and StAR protein (Wang et al., 2002). These results were reversed when
AA was added to cells. Although c AMP induces release of AA, addition of AA
metabolites to MA-10 cells with low concentrations of eAMP increased StAR expression
and steroidogenesis (Wang et al., 2003). Furthermore, steroidogenic cells incubated in
Ca2+ free medium and treated with maximal stimulating concentrations of LH/hCG
resulted in a 50% decrease in steroid production and decreased StAR expression (Sulivan
and Cooke; 1986; Ramnath et al., 1997; Manna et al., 1986). Therefore, it seems that
these pathways regulate steroidogenesis in different ways. Sullivan and Cooke (1986)
suggest that sub-maximal concentrations of steroid hormones are regulated primarily by
the Ca2+ messenger system while maximal testosterone concentrations are regulated by
both the Ca2+ messenger system and the cAMP-dependent pathway.
It is important to note that the cAMP-mediated pathway alone does not yield
maximum steroid production; rather it is the co-regulation of c AMP-dependent and
cAJVIP-independent pathways (Wang X et al., 2002). The cAMP-independent pathways
have been studied to a lesser degree. Manna et al. (2006) showed that insulin-like growth
factor (IGF), epidermal growth factor (EGF), fibroblast growth factor (FGF),
transforming growth factor a (TGFa), interleukin-1 (IL-1), and colony:stimulating factor1 (CSF-1) increase StAR mRNA expression and P4 secretion without stimulating cAMP.
Transforming growth factor a increases StAR mRNA and P4 by binding to the epidermal
growth factor receptor (EGFR), a single transmembrane receptor. Therefore, it was
•
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hypothesized that TGFa increases steroidogenesis through the mitogen-activated protein
kinase (MAPK) pathway. This sequence of events includes TGFa binding to EGFR
causing homodimerization of the receptors and autophosphorylation of their tyrosine
tails. As a result, growth factor receptor-bound protein 2 (Grb2) and Son of Sevenless
(SOS) form a complex and dock on the phosphorylated tyrosine tail. The SOS protein
becomes activated and removes guanosine diphosphate (GDP) from Ras so that it
becomes activated by binding GTP. Activated Ras phosphorylates the protein kinase
RAF, which, in turn, phosphorylates MAPK/ERK kinase (MEK). The MEK protein
activates mitogen-activated protein kinase (MAPK), inducing transcription of StAR.
However, inhibition of this pathway resulted in different effects on steroidogenesis;
stimulation (Seger et al., 2001; Tajima et al., 2003), inhibition (Gyles et al., 2001; Manna
et al, 2002; Martinelli et al., 2004), or no effect (Tai et al., 2001; Seto-Young et al.,
2003; Tajima et al., 2005).
While the stimulation of steroidogenesis is driven primarily by LH and hCG
through the cAMP-dependent pathway, inhibition of steroidogenesis is driven by the
protein kinase C (PKC) pathway (Conley and Ford, 1989; Wiltbank et al., 1989; McGuire
eta al., 1994). Ovine luteal cells deficient in PKC do not respond to PGF2a with a
decrease in P4 (Wiltbank et al., 1990). Therefore, it appears that PGF 2a exerts its antisteroidogenic effect through this pathway. In order to elicit a response, PGF 2a binds to its
receptor (FPr), a 368 amino acid 7-transmembrane receptor (Fitz et al., 1982; Kyte and
Doolittle, 1982; Gadsby et al., 1990; Graves et al., 1995). The FPr is present on large, but
not small luteal cells (Fitz et al., 1982; Balapure et al., 1989; Coleman et al., 1994;
Juengel et al., 1996). This binding leads to activation of the G-coupled protein which, in
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turn, activates phospholipase C (PLC). Phospholipase C is an enzyme that cleaves
phosphotidylinositol 4,5-biphosphate (PIP2), which is found in the cell membrane, into
two products: diacylglycerol (DAG), which remains in the cell membrane, and inositol
triphosphate (IP3), which acts on the endoplasmic reticulum causing the release of Ca2+
into the cytoplasm. Diacylglycerol and Ca2+ activate PKC which then inhibits
steroidogenesis possibly by decreasing P450scc and 3/3-HSD mRNA expression (Cooke
and Robaire, 1988; Hawkins et al., 1993) or by decreasing cholesterol transport into the
mitochondria (Wiltbank et al., 1993). Interestingly, PKC increases intracellular Ca2+ and
the transcription and translation of StAR, similar to the response of the cAMP/PKA
pathway; however, the protein produced in response to PKC is not phosphorylated (Jo et
al.,2005).

StAR Gene Regulation:
The StAR gene is transcriptionally regulated by several factors. Steroidogenic
factor-1 (SF-1) is a member of the steroid hormone receptor family of nuclear
transcription factors and is essential for protein-DNA interactions and maximal
transcription of the StAR gene (Wooton-Kee and Clark, 2000). It binds to five sites in the
mouse promoter and six in humans (Caron et al., 1997; Sugawara et al., 1997; Sandhoff
et al., 1998). Another group of proteins that helps regulate StAR expression is the
CCAAT/enhancer binding proteins (C/EBP), a family of leucine zipper transcription
factors (Johnson and Williams, 1994). Two specific members include C/EBPaand
C/EBP/3, which are phosphoproteins targeted by PKA (Roelser et al., 1998). The StAR
promoter contains two binding sites for C/EBPs. It was found that C/EBP/3 binds to at
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least one of these sites and induces transcription of the StAR gene. These functional
- binding sites are also essential for transcription of the StAR gene by,SE-l, suggesting that
SF-1 and C/EBP/3 form a complex on the promoter (Stocco DM et al., 2001). A third
factor involved with the regulation of StAR is SP-1, a member of the zinc finger family
of transcription factors (Berg, 1992). This factor is involved in up-regulating several
P450scc genes as well as StAR (Stocco et al.,.2001). It interacts with the estrogen
receptor (Sun et al., 1998) and C/EBP/3 (Lee et al., 1997) to stimulate the expression of
StAR. Another important activator of the StAR gene is thought to be GATA-4, which is
present in porcine corpora lutea and is expressed constitutively in granulosa cells (GillioMenia et al., 2003). Silverman et al. (1999) located the binding sequences of GATA-4
and C/EBP/3 on the StAR promoter. Mutagenesis of both sites resulted in a lack of
promotor activation. Since GATA-4 is constitutively expressed while C/EBP/3 expression
increases in response to LH and FSH, it is likely that GATA-4 plays a more permissive
role in StAR regulation while C/EBP/3 plays more of a central role (Sugawara et al.,
1997). The steroid regulatory element binding protein (SREBP) was also shown to
increase transcription of the StAR gene; however, no binding sites on the StAR promoter
for this protein have been found (Christenson et al., 1998). Similarly, cAMP response
element binding protein (CREB) increases steroidogenesis, StAR promoter activity, and
StAR mRNA expression, but no consensus cAMP response element has been found on
the StAR promotor, suggesting that CREB helps regulate StAR expression possibly
through a non-consensus sequence or by indirectly binding to the promoter (Stocco et al.,
2001). Unlike the stimulators, the inhibitors of the StAR promoter are less studied. One
of them is D AX-1, a protein that is part of the nuclear hormone receptor family.
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Overexpression of DAX-1 in mouse adrenal tumor cells blocks steroid biosynthesis by
inhibiting P450scc and 3/3-hydroxysteroid dehydrogenase (3/3-HSD; Zazopoulos et al.,
1997; Lalli et al., 1998). It has been shown that DAX-1 interacts with SF-1 to impair
transcription (Ito eta al., 1997). In addition, DAX-1 binds directly to the StAR promoter,
blocking expression of the gene (Manna et al., 2008).

Possible Mechanisms of Cholesterol Transport by StAR:
The mechanism of how StAR transports cholesterol into the mitochondria is not
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fully elucidated, but several hypotheses have been suggested. Kallen et al. (1998a)
proposed that the StAR C-terminus, which contains the START domain, induces changes
in the outer mitochondrial membrane resulting in the transport of cholesterol to the inner
mitochondrial membrane. Furthermore, Kallen et al. (1998b) suggest that StAR interacts
directly with the outer mitochondrial membrane and not through an intermediate protein.
Similarly, Stocco and colleagues suggest that once StAR anchors itself to the
mitochondrial membrane via the targeting sequence, a lipid bridge forms between the
inner and outer mitochondrial membranes (Clark et al., 1994; Stocco and Clark, 1996).
Subsequently, the 37 kDa form of StAR transports cholesterol into the mitochondria and
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is cleaved by matrix processing proteases in the mitochondria resulting in the 32 kDa
intermediate form. The inner and outer mitochondrial membranes separate and the 32
kDa form of StAR is cleaved to yield the 30 kDa form, which is nb longer able to aid in
cholesterol transport. However, Arkane et al. (1996) showed that steroidogenic capacity
was not affected in cells containing StAR proteins with deletion of 62 residues on the N-
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terminus (the mitochondrial targeting sequence), which suggests that steroid synthesis is
possible when StAR remains on the outside of the mitochondria.
An alternative hypothesis, called the molten globule hypothesis, has been
proposed by Bose et al. (1999). A protein that is in the molten globule state is slightly
denatured to yield a different conformation than its native state. They suggest that StAR
undergoes a~conformational change near the mitochondria because of the acidic
microenvironment produced by the proton pump. As a result, the positively charged Cterminal domain is exposed and may interact with the negatively charged mitochondrial
membrane or a receptor. This suggestion was further strengthened when Papadopoulos
(1993) proposed that a peripheral benzodiazepine receptor (PBR), which is found in high
abundance on the outer mitochondrial membranes of steroidogenic cells, is involved with
cholesterol transport into mitochondria. Disruption of PBR in rat tumor Leydig cells
resulted in a 90% decrease in steroid secretion, while reintroduction of this receptor
resulted in normal steroid secretion (Papadopoulos et al., 1997). To show that PBR is
linked to cholesterol uptake by mitochondria and not linked to the secretion of steroids by
cells, Li and Papadopoulos (1998) transfected E. coli DE3 cells with PBR to induce
mitochondrial uptake of cholesterol. Since StAR and PBR increase steroidogenesis, West
et al. (2001) inquired if these two proteins interact to transport cholesterol into
mitochondria. Their results led them to hypothesize that cholesterol binds to StAR either
in the cytoplasm or to StAR already imbedded in the mitochondrial membrane, which
then presents cholesterol to PBR so that it transports cholesterol into the inner
mitochondrial membrane. However, Kallen et al. (1998a) found that StAR transported
cholesterol into the mitochondria whose outer membrane proteins were removed or
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partially lysed with trypsin. Subsequently, Christensen et al. (2001) supported this work
when they found that recombinant StAR bound to mitochondrial membranes without any
associated proteins.
Although there are many hypotheses of how cholesterol is transported into
mitochondria, the one proposed by Stocco's group is the most plausible. Their three
pieces of evidence are the most compelling: (1) The START domain of StAR binds
cholesterol in a 1:1 ratio. (2XMitochondria lacking membrane associated proteins, such as
PBR, still exhibit transport of cholesterol by StAR. (3) The active form (37 kDa) of StAR
is found in the cytoplasm while the intermediate (32 kDa) and inactive (30 kDa) forms
are found within the mitochondria. Not only is StAR primarily responsible for cholesterol
transport into the mitochondria, but it is also the acute regulatory protein involved in
steroidogenesis and it is important to understand why. The following criteria define an
acute regulatory protein: 1) a protein newly synthesized within minutes to hours {de novo
synthesis) in response to a hormonal stimulus, 2) the protein's synthesis has to be
sensitive to cycloheximide (an inhibitor of de novo protein synthesis), and 3) the protein
is localized in the mitochondria.

Other Cholesterol Carrying Proteins involved in Steroidogenesis:
Although StAR is known as the acute regulator in steroid biosynthesis, it is
important to keep in mind that there are other cholesterol transporting proteins that affect
steroidogenesis. One of these proteins is sterol carrier protein 2 (SCP2), which is a 13
kDa protein found in the liver, adrenal, and corpus luteum (Chanderbhan et al., 1982;
Vahouny et al., 1987). The role of this cycloheximide resistant protein is to transport
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lipids, one of which is cholesterol. It binds cholesterol in a 1:1 molar ratio within the cell;
it is concentrated in peroxisomes, and it is minimally detected on mitochondria (MendisHandagama et al., 1995). However, when treated with LH, SCP2 is concentrated in
peroxisomes, mitochondria, and lipid droplets in luteal cells suggesting that SCP2
transports cholesterol from lipid droplets to mitochondria for steroidogenesis. Another
protein is the steroidogenesis activator protein (SAP), a 3.2 kDa protein found only in
steroidogenic cells (Pedersen and Brownie, 1987; Mertz and Pederson, 1989). It is a
cAMP-dependent protein. Pedersen (1987) found that SAP and P450scc activity is
upregulated by hCG treatment suggesting that SAP is a key regulator of P450 activity.

Progesterone Biosynthesis:
Progesterone (P4) is a 21 carbon steroid hormone discovered by Corner and Allen
(1929) and subsequently isolated from rabbit ovary (Allen, 1935). It maintains pregnancy
by inhibiting uterine contractions (Allen, 1935), thickening cervical mucus, and building
the endometrium for implantation of the fetus (Zarrow, 1965). Steroid biosynthesis
encompasses a cascade of enzymatic reactions which begins with cholesterol, the
precursor for all steroid hormones (Christenson and Devoto, 2003). A steroidogenic cell
has three sources of cholesterol; 1) LDL/HDL from the bloodstream, 2) lipid droplets
within the cell, and 3) intracellular synthesis of cholesterol from acetate (Grummer and
Carroll, 1988). The steroidogenic cells of most species utilize exogenous sources of
J

cholesterol found in LDL and HDL rather than synthesizing cholesterol from acetate.
Mice, rats, and ruminants primarily utilize HDL as a source of cholesterol while humans,
6]

rhesus macaques, and pigs use LDL (Christenson and Devoto, 2003). When a
steroidogenic cell engulfs LDL or HDL by receptor-mediated endocytosis, cholesterol is
cleaved by acid lipases and is transported into the mitochondria by StAR. Luteinizing
hormone drives cleavage of cholesterol from lipid droplets in steroidogenic cells by
binding to its 7-transmembrane receptors on small and large luteal cells. As a result, the
G-protein activates adenylate cyclase and produces cAMP. This activates PKA which
activates cholesterol ester hydrolase, also known as hormone sensitive lipase. This
enzyme cleaves cholesterol from cholesterol esters that are stored in lipid droplets within
the cell allowing free cholesterol to be transported into the mitochondria by StAR.
Although both small and large luteal cells produce P4 in response to LH, it is important to
keep in mind that P4 production is increased 5-15 fold in response to elevated
concentrations of LH by small, but not large luteal cells (Niswender, 2002). During the
luteal phase of the estrous cycle, high concentrations of circulating P4 result in low
frequency secretion of LH (Lucy et al., 1992). If there is not enough cholesterol available
either in the bloodstream or in lipid droplets, the steroidogenic cell synthesizes
cholesterol from acetate. Obtaining cholesterol by this method requires a lot of energy so
the cells use it as a last resort for steroid production.
Once a steroidogenic cell obtains cholesterol from one of these three sources,
StAR transports it into the mitochondria where 20,22 lyase (P450scc) converts it to
pregnenolone (Figure 11; Geslin and Auperin, 2004). Pregnenolone is then converted to
progesterone by the enzyme 3/3-hydroxysteroid dehydrogenase (3/3-HSD) in the smooth
endoplasmic reticulum (Christenson and Devoto, 2003).
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Figure 11.

Progesterone Biosynthesis

«yc

Cholesterol

HafC

P450scc

• O

.!%C
J

Pregnenolone

-H*C
^*^ -«**.

30HSD

..<>
IfcC

H«C

Progesterone
j^S*»

O*

StAR and Progesterone Expression during the Estrous Cycle and Luteolysis:
During functional luteolysis in a variety of species, PGF2« initiates a cascade of
events that results in decreases in StAR expression and-P4 concentrations. Edqvist et al.
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(1975) injected a single 25 nig dose of PGF2ainto cows on either-day 8 or 14 of the
estrous cycle and found that plasma!^ concentrations decreased in all cows 24 hours
after treatment. Pescador et al. (1996) measured StAR protein levels in bovine corpora
lutea and found that they were low during CL development, high during the midluteal
phase, and disappeared 24 hours after a single 500 ug injection of a PGF 2a analogue.
Similarly, Fielder et al. (1999) found that StAR protein and P4 concentrations are lower in
day 7 post ovulatory rat corpora lutea after a single 250 ug (i.p.) injection of PGF2Q when
compared to controls. However, the level of StAR mRNA in PGF2ortreated rats was not
different from controls suggesting that the decrease in StAR protein is not due to a
decrease in StAR gene expression, but rather post transcriptional inhibition. In addition,
rat luteal cells treated with increasing amounts of PGF2« resulted in a dose-dependent
decrease of StAR protein (Liu et al., 2007) In the mare, plasma P4 decreases 24 hours
after a single (i.m.) injection of either 0.8 mg/100 kg, 0.4 mg/100 kg, or 0.2 mg/100 kg of
PGF2aon day 7 of the estrous cycle when compared to controls (Handler et al., 2004). A
similar experiment involving mares treated with 10 mg of PGF2a on day 9 after ovulation
showed a decrease in progesterone (<1 ng/ml) 24 hours after treatment when compared to
controls (Vanderwall et al., 2000). Liu et al. (2003) found that the expression of StAR in
the rhesus monkey corresponded to the decline in P4 in the late luteal stages. Plasma P4
and total protein decrease during natural luteolysis in women when compared to early
and mid lutealphases (Del Canto et al., 2007). Similarly, StAR mRNA and P 4 decreased
in human CLs treated with PGF 2a (Chung et al.,. 1998). Juengel et al. (1995) treated sheep
with two (i.m.) injections (10 mg or 25 mg) of PGF2« on days 11-12 of the estrous cycle.
Blood samples and CLs were taken 4, 12, or 24 hrs after treatment and from control
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animals. Serum P4 concentrations and StAR mRNA were decreased at all time points in
treated animals.
Because of the pulsatile release of PGF2a in ruminants, would the temporal pattern
of StAR expression and progesterone concentration differ in animals receiving a bolus
dose? To,answer this question, Allen (UNH Master's thesis), Towle et al. (2002), and
Ricketts (UNH Master's Thesis) used a model in which sheep receive one or two
infusions of PGF2a to mimic physiological conditions during the onset of luteolysis.
Progesterone transiently decreased by 40% (p<0.05) 8 hours after a single one hour
systemic infusion of PGF2a (0.22 ug/kg/min), while StAR expression remained
unchanged. Eight hours following a second one hour systemic infusion of PGF2tt(0.22
ug/kg/min), P4 concentrations decreased by 40% (p<0.05). It then rose above pre-infusion
levels 24 hours after PGF 2a treatment (p<0.05) while StAR expression remained
unchanged throughout the experiment.

Other Factors Contributing to Luteolysis:
While the present study focused on the effects of PGF 2a on MMPs, TIMPs, StAR,
P4 and COX expression, it is important to note that other factors are also involved in
luteolysis. They are briefly reviewed below.
Structural regression of the CL is accompanied by DNA fragmentation and
apoptosis. Juengel et al. (1993), McGuire et al. (1994), Rueda et al. (1995), and Juengel
et al. (2000) found that increased intracellular Ca2+ causes DNA fragmentation in the cow
and ewe during luteal regression. Niswender et al. (2007) proposed that PGF2a binds to
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large luteal cells to increase PKC and oxytocin in large luteal cells (Flint and Sheldrick,
1982). As a result, oxytocin binds to small luteal cells to increase PKC which decreases
P4 production. Along with the increase in PKC in both cell types, there is an increase in
intracellular Ca2+ which causes DNA fragmentation and apoptosis, marking structural
luteolysis. Although oxytocin is secreted by large luteal cells (Cosola-Smith et al., 1990;
Wathes and Denning-Kendall, 1992), Hoyer (1998) found that oxytocin causes DNA
fragmentation in large, but not small ovine luteal cells suggesting that large luteal cells
use an autocrine signal for apoptosis. Okuda et al. (1992) found that bovine luteal cells
contain oxytocin receptors, but were unable to distinguish small from large luteal cells.
However, Niswender at al. (2007) reported that small luteal cells isolated from ewes
showed a dose-dependent response to oxytocin suggesting that they have oxytocin
receptors. Another effect of oxytocin is the stimulation of uterine PGF20, (Sharma and
Fitzpatrick, 1974; Roberts and McCracken, 1976). As a result, uterine and luteal PGF2«
are produced to enhance regression of the CL.
Nitric oxide (NO) has been implicated in CL function. Keator et al. (2008) have
shown that NO has a luteolytic effect in sheep. In their study, ovaries were transplanted
to the neck so uterine PGF2tt could not induce luteolysis. Sheep with a day 11 CL
received a single 1, 10, 100, or 1000 ug infusion of dipropylenetriamine NONOate
(DPTA), a fast-acting nitric oxide donor. Progesterone concentrations decreased 24 hours
after infusion of 1000 mg/min of DPTA. Microdialysis was used to perform an in vivo
perfusion nitric oxide donor spermine NONOate (100 mg/4 hrs) into the CL of cows on
day 12 of the cycle resulted in no change in P4 concentration (Jaroszewski et al., 2003).
However, Jaroszewski and Hansel (2000) infused cows with the nitric oxide synthase
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(NOS) inhibitor L-NAME on days 11 or 12 and days 17 and 18, and found that P4
concentrations remained increased in all three groups through day 25 of the cycle,
suggesting that NO inhibits P4 secretion by the CL. When a mixture of small and large
bovine luteal cells in culture were treated with 100 ng/4 hrs spermine NONOate, P4
concentration decreased. Similar results were also reported by Skarztnski and Okuda
(2000) and Korzekwa et al. (2004).
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Reactive oxygen species (ROS), which are free radicals, have also been suggested
to play a role in regression of the CL. Xanthine oxidase, an enzyme that generates the ••
ROS superoxide, inhibits P4 production by rat luteal cells (Gatzuli et al., 1991).
Furthermore, hydrogen peroxide, another ROS, blocks hormone-sensitive cholesterol
transport into the mitochondria of rat luteal cells (Behrman and Aten, 1991). In addition
to being involved in functional regression, ROS may contribute to structural regression.
Tilly and Tilly (1995) showed that ROS are associated with apoptosis of granulosa cells
undergoing atresia. Sawada and Carlson (1989) showed that ROS increase in response to
PGF2a in the rat. Furthermore, superoxide dismutase, an enzyme that protects against
ROS, is reduced during luteolysis in cows and sheep (Rueda et al., 1995b; Hoyer, 1998).
Immune cell products such as tumor necrosis factor a (TNFa), interleukin-1 (IL1) and IL-2 may also contribute to CL regression. Interleukin-1 /3-converting enzyme
mRNA and TNFa are upregulated during luteolysis in cows (Shaw and Britt, 1995;
Rueda et al, 1997). These cytokines, especially TNFa, inhibit basal and hCG-induced P4
production in pigs (Pitzel et al., 1993). In addition, TNFa, IL-1/3, and interferon y (IF7)
inhibit P4 production in cultured bovine luteal cells (Townson and Pate, 1994; Pate,
1995). Immune cells also contribute to the structural demise of the CL. Hehnke et al.
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(1994) found that macrophages increased 24 hours after PGF2<r induced luteolysis in the
pig. Paavola (1979) reported that macrophages ingest luteal cells by phagocytosis in the
guinea pig CL. Similarly, macrophages, leukocytes, and T-lymphocytes increase during
regression of the CL in the cow (Penny et al., 1999). The products of these immune cells
include TNFo!, IL-1 and IFN7, which increase PGFi a production (Townson and Pate,
1994; Pate, 1994) and promote DNA fragmentation and apoptosis of luteal cells.
The 21 amino acid protein endothelin-1 (ET-1) has also been associated with the
functional demise of the CL (Hinckley and Milvae, 2001). It is part of a family of
proteins that includes ET-2, ET-3, and sarafotoxin (Inoue et al., 1989). Endothelin-1 is a
potent vasoconstrictor; it is present in a variety of tissues and is produced by endothelial
cells (Yanagisawa et al., 1988). Endothelin-1 also stimulates phdspholipase C,
phospholipase A2, phospholipase D,cAMP accumulation, arachidonic acid release, and
prostanoid production (Muldoon et al., 1989; Resnick et al., 1989; VanRenterghem et al,
1989). The two receptors for endothelins have been identified as ETA and ETB (Maggi et
al, 1989), with ETA having a higher affinity for ET-1 and -2 than it does for ET-3. All
three endothelins have the same affinity for the ETB receptor (Naruse et al., 1994).
Mamluk et al. (1999) showed that both small and large luteal cells contain mRNA for the
ETA receptor, making ET-1 a likely mediator of luteolysis. To investigate the function of
ET-1 in the corpus luteum, Girsch et al. (1996a) conducted an in vitro study involving
ovine and bovine luteal cells treated with ET-1. The result was a decrease in basal and
LH-stimulated P4 production. Hinckley et al. (1996) showed that in vitro treatment of
bovine luteal cells with the ETA antagonist BQ123 before addition of ET-1 resulted in no
change in basal or LH-stimulated P4 production. Thus, the inhibitory action of ET-1 on P4
68

production is mediated through the ETA receptor, Given that ET-1 decreases P4
production, it is hot surprising that ET-1 content is low in the young CL (days 5-6),
higher in the mature CL (days 9-16), and highest in the late CL (days 17-21) during the
bovine estrous cycle (Milvae, 2000). Since ET-1 production increases around the same
time as PGF2a (late luteal phase), it is also not surprising that Miyamoto et al. (1997)
showed that intraluteal administration of PGF2a to bovine luteal tissue in vitro resulted in
an increased output of ET-1 as well as a decrease in P4 concentration. Further, in vivo
treatment with either 100 ug of ET-1 or a subluteolytic dose of PGF2a resulted in
decreased P4 production, but cycle length was not affected in midcycle sheep (Hinckley
et al., 1998). However, when sheep were treated with both ET-1 and a subluteolytic dose
of PGF^a, a greater decrease in P4 was observed which was accompanied by a shortened
cycle length (10.3 days). Furthermore, pretreatment with BQ123 mitigated the luteolytic
^
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effects of PGF2« in cows (Girsh et al., 1996b). These results suggest that the effects
PGF2« are, in part mediated through ET-1 binding td ETA receptors.
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CHAPTER II

TEMPORAL EXPRESSION OF PROGESTERONE AND
PROTEINS DURING PROSTAGLANDIN F2a-INDUCED
LUTEOLYSIS IN THE SHEEP

INTRODUCTION
The luteal phase of the sheep estrous cycle is 14 days long and is dominated by
the corpus luteum (CL), a transient endocrine gland that secretes the steroid hormone
progesterone (P4; Casida and Warwick, 1945; Edgar and Ronaldson, 1958). Progesterone
thickens cervical mucus, and builds the endometrium for implantation of the fetus
(Zarrow, 1965). During pregnancy, the CL continues to produce P4 to inhibit uterine
contractions (Allen, 1935; Dutta and Sanyal, 1969; Morishita, 1986; Kostrzewska et al.,
1993; Ruddock et al., 2008). However, if pregnancy does not occur, the uterus secretes
the eicosanoid hormone prostaglandin Y{a (PGF2a) in a pulsatile manner to cause
regression of the CL, a process known as luteolysis (McCracken et al., 1972; Zarco et al.,
1988). On average, four to five sequential pulses of PGF2a are required for complete
luteal regression (Schramm et al., 1983; McCracken et al., 1999). Following PGF2tt, the
CL undergoes structural regression, which is characterized by degradation of the
extracellular matrix (ECM) and apoptosis of luteal cells (Umo, 1975; Hoyer, 1998;
Stocco et al., 2007), and functional demise, which is defined as a decrease in P4
production.
•'
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The ECM is composed of many proteins, which serve as anchorage points for
cells and aid in cell-to-cell interactions, cell migration, cell replication, and
morphogenesis (Gumbiner, 1996; Yamada and Geiger, 1997; Geigeretal., 2001). The
ECM of the CL is composed primarily of collagen types I and IV, fibronectin and laminin ,N
(Silvester and Luck, 1999; Irving-Rogers etal., 2006). The structural integrity of the
ECM is regulated by the net balance between proteolytic enzymes called matrix
metalloproteinases, (MMPs) and their endogenous inhibitors, tissue inhibitors of
metalloproteinases (TIMPs). Matrix metalloproteinases are a diverse family of divalent
cation-dependent enzymes that degrade all the components of the ECM (Roy, 2006)
while TIMPs inhibit MMPs by forming reversible, non-covalent complexes with them in
a 1:1 ratio. When the balance between MMPs and TIMPs tips in favor of net proteolysis,
the integrity of the ECM is compromised, i.e. structural regression of the CL occurs
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(Zhao and Luck, 1995; Kliem et al., 2007). Among the members of these enzyme and
inhibitor families, the gelatinases, MMP-2 and -9, and TIMP-1 and -2 are among the
most well studied. Several studies in a number of animals have shown that MMP-2 and -9
expression increases during natural luteolysis (Pitzel et al., 2000; Xinlei et al., 2006;
Kliem et al., 2007) and in TNFa treatmented corpora lutea (Zhang et al., 2005),. The
same has been done following prolactin-induced (Endo et al., 1993) and PGF2a-induced
(Kliem et al., 2007) luteolysis, while TIMP-1 (Zhang et al., 2003) and TIMP- 2 decrease
(Smith et al., 1995; Inderdeo et al., 1996; Mclntush and Smith, 1999; Kliem et al., 2007).
Fewer studies have determined the protein expression of these endpoints during CL
regression (Li et al., 2002; Young et al., 2002; Chen et al., 2006; Ribeiro et al, 2006).
Collectively, the increase in enzymes along with the decrease in inhibitors results in net
.
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proteolysis, which is an integral part of the complex processes that contribute to the
structural demise of the CL.
Accompanying the structural regression of the CL is its functional decline, as
marked by a decrease in P4 production (Juengel et al., 1993; Tian et al., 1994; Juengel et
al, 1995 Hoyer, 1998; Stocco et al., 2007). Essential for the synthesis of P4 is the
steroidogenic acute regulatory (StAR) protein, which is responsible for transporting
cholesterol into mitochondria so that it can be converted into- pregnenolone and
subsequently into P4 (Stocco and Sodeman, 1991). A single (Edqvist et al., 1975;
Pescador et al., 1996; Vanderwall et al., 2000) or multiple (Juengel' et al., 1995)
supraphysiological doses of PGF2tt administered to various animals results in a decrease
in serum P4 concentrations and luteal StAR mRNA and protein expression. Indeed, these
two endpoints are good indicators of the functional status of the CL.
While PGF2a from the uterus initiates luteolysis in several species (McCracken et
al., 1972; Nancarrow et al., 1973; Gleeson et al., 1974; Poyser, 1976), it is also produced
by the CL of various animals (Guthrie et al., 1978; Rexroad and Guthrie, 1979; Milvae
and Hansel, 1983; Johnson et al., 1988; Pate, 1988). The synthesis of prostaglandins
1

requires the cyclooxygenase (COX) enzymes, which are responsible, for converting
arachidonic acid into prostaglandins (Samuelsson et al., 1978; Pagel et al., 1983; Smith,
1992; Levy et al., 2000), Because COX-1 is constitutively expressed in the CL (DeWitt et
al., 1983; Funk et al., 1991; Kraemer et al., 1992; Arosh, 2004; Zerani et al., 2007), it is
COX-2, the inducible isoform, which has received considerable attention regarding its
role during luteolysis. Expression of luteal COX-2 mRNA and protein increases during
natural luteolysis or in response to varying doses of PGF2« (Tsai and Wiltbank, 1997;
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Hayashi et al., 2003; Arosh et al., 2004). The increase in COX-2 during luteolysis
therefore leads to an increase in PGF2a secretion by the CL (Rexroad and Guthrie, 1979;
Guthrie and Rexroad, 1980b). As a result, an autocrine pathway is established in which
the result is amplification of luteal PGF2a. Thus, both uterine and luteal PGF2tt contribute
to the eventual demise of the CL.
Uterine PGF2a is released in a pulsatile fashion during natural luteolysis in
ruminants. In order to profile the dynamic changes in progesterone and proteins
associated with luteolysis following each pulse, we developed a model in sheep whereby
timed infusions of PGF2« (-0.22 ug/kg/min) are started on day 11 of the estrous cycle.
Plasma P4 decreased by 40% after one and two infusions of PGF2a (Towle et al., 2002,
Ricketts, UNH Master's Thesis), which mimics the 40% decline in P4 that occurs after
the first pulse of PGF2« during natural luteolysis in sheep (Custer et al., 1997).
Interestingly, StAR expression transiently declined following the first PGF2«,but did not
mirror the P 4 profile after the second infusion. On the other hand, the TIMPs fell
significantly at the onset of luteolysis before recovering, while MMP-2 activity
transiently increases. As expected, there were no changes in COX-1 expression, while
COX-2 increased 16 hours following the first infusion of PGF2a and remained increased
after the second infusion (Allen, UNH Master's Thesis; Ricketts, Master's Thesis).
Thus far, it appears that the luteolytic machinery is set in motion following one or
two infusions of PGF2a, but they are not adequate to induce luteolysis in sheep. However,
following three sequential infusions of PGF2<» approximately 33% of treated sheep
undergo luteal regression (Schramm et al., 1983; McCracken et al., 1999). Given this,
how different are the pattern of P4 concentration and expression of proteins associated
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with luteolysis following three infusions of PGF2tt compared to one or two? To answer
this question, the current study determined the expression of MMP-2 and-9, TIMP-1 and
-2, COX-1 and -2, StAR, and P4 in the sheep corpus luteunrfollowing three infusions of
PGF2a.
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Materials and Methods
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Animal model of PG'F2>rinduced luteolysis:
A single one hour systemic infusion of PGF2a (~0.22ug/kg/min) can be
administered at midcycle to mimic physiological conditions during the onset of luteolysis
in sheep (Custer et al., 1995). This infusion rate causes a 40% decline in P4 after one and
two systemic infusions of PGF2tthave passed through the lungs and reached the ovary
(Towle et al., 2002; Ricketts, UNH Master's Thesis), A similar decline in P4 is seen
under physiological conditions during the onset of luteolysis (Zarco et al. 1988). This
established model was used in the present study to determine the in vivo changes in
several molecular mediators of luteolysis following three systemic infusions of PGF2a,
with the second and third infusions given 16 and 24 hours after the first pulse,
respectively. Below is a depiction of the experimental model (Figure 12):
Figure 12:

Day 11 of Estrous Cycle
Infusions of PGF2p
1st

2nd

n

n

3rd

n

01 234...161718...23 24 2526 27 28 29 30 31 32 33343536 373839 404142 4344454647 48
0

- 1 1

8

16

Time of Luteectomy(n=4 for each time point)

Figure 12: Brackets indicate 1 hour systemic infusions of PGF^a (-.22 ug/kg/min) while
triangles indicate time of luteectomy. Time 0 represents untreated animals and serves the
control. The-1 hour time point corresponds to animals that received two infusions of
PGF2a before CLs were removed one hour prior to giving the remaining animals a third
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infusion of PGF2a. Luteectomies were performed 1, 8, 16, 24 hours following the third
infusion. For each time point n = 4.

Tissue Collection and Preparation:
Luteal tissue was collected and prepared as previously described (Towle et al.,
2002). Briefly, a group of mixed Dorset and Suffolk ewes (Ovis aries; ~90 kg) were
housed at the University of Connecticut (Storrs, CT) and their estrous cycles
synchronized with two intramuscular injections of Lutalyse (5mg; UpJohn Co.;
Kalamazoo, MI) given at 4 hour intervals. Ewes were observed twice daily for estrus
j
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(Day 0) using a vasectomized ram. On the eleventh day post estrus, ewes were placed in
metabolism cages and 16 gauge cannulae were inserted into both jugular veins, while
under local anesthesia (2% [w/v] lidocaine). Three one hour systemic infusions of PGF2a
(UpJohn Co.) were administered to the right jugular vein via a Harvard infusion pump
(model no. 600-910/920; Harvard Apparatus Co.; Holliston, MA) at a rate of-0.22
ug/kg/min (Custer et al., 1995). To mimic physiological pulses, the second and third
infusions of PGF2a were given 16 hours and 24 hours after the first, respectively. Control
animals received saline. Corpora lutea were removed surgically via flank laparotomy
under local anesthesia (2% [w/v] lidocaine) from untreated animals (designated 0 hr).
Corpora lutea were also removed one hour before the third infusion of PGF2«, (designated
-1 hr) and 1, 8, 16, 24 hrs after the third PGF2« infusion (n = 4 sheep for each time point).
After collection, luteal tissues were immediately placed on dry ice and stored at -80°C.
For analysis, individual samples representing each of the six time points were analyzed in
four sets of sixr
.

'

76

To monitor peripheral plasma progesterone, jugular blood samples (5 ml) were
collected hourly into heparinized tubes via the left jugular vein cannula from time zero
until the time of individual luteectomy. Blood samples were taken 4, 8, 12, 16, and 20
hours after the first infusion of PGF2a and then every hour until luteectomy. All
experimental procedures received prior approval by the University of Connecticut
Animal Care and Use Committee.

Protein extraction;

c

Luteal tissue proteins (MMP-2 and -9, TIMP-1 and -2, StAR, and COX-1 and -2)
were extracted with a buffer (50mM Tris HC1, 150 mM NaCl, 0.02%. [w/v] sodium azide,
10 mM EDTA, 1% [v/v] Triton X-100, pH 7.4) containing protease inhibitors (lug/ml
AEBSF, lug/ml pepstatin A, 10 ug/ml aprotinin) in a ratio of 1 g tissue to 8 ml extraction
buffer, as previously described (Zhang et al., 2002). Tissue was homogenized with a
Kinematic Polytron, and the homogenate was then centrifuged at 10,000 x g for 10
minutes at 4°C. The supernatant between the pellet and fat layer was then removed and
the centrifugation step was repeated until no pellet was observed. The supernatant was
then stored at -80° C until used for analysis of MMP-2 and -9 by gelatin zymography and
analysis of TIMP-1 and -2 and StAR by immunoblotting. For COX-1 and -2 analysis, a
portion of the sample was removed after homogenization and sonicated twice for 5
seconds (Sonifer Cell Disruptor 350, Branson Sonic Power Co.) prior to centrifugation,
as described above. The complete extraction protocols are found in Appendix A.
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Protein Concentration Determination;
Protein concentrations were determined by the Bradford Method (Bradford, 4 976)
using Coomassie Blue (Bio-Rad Bradford Assay Reagent, Hercules, CA, USA). Bovine
serum albumin (Sigma; St Louis, MO, USA) dissolved in CAB+ buffer (0.2M NaCl,
ImM CaCl2, 50mM Tris, 0.02% NaN3, pH 7.6) was the protein standard. Optical
densities were read at 595 nm using a spectrophotometer (model DU640; Beckman
Instruments; Fullerton, CA, USA). All luteal tissue samples were diluted 1:10 with
CAB+ buffer and 2.5 ul and 5ul aliquots in duplicate were assayed. Details are in
Appendix B.

<

Immunoblot Analysis;
Equal volumes of luteal tissue extract were loaded on SDS-P AGE gels (12.5%
[w/v] for TIMP-1, TIMP-2, StAR, COX-1, and COX-2. Except for TIMP-1, all were run
under reducing conditions (5%. [v/v] 2-mercaptoethanol, 100°C for 5 minutes), at 200
volts for 45-60 minutes, along with the dual color, pre-stained SDS-P AGE marker
standards (Bio-Rad Laboratories, Hercules, CA, USA). Separated proteins were
transferred to a Protran nitrocellulose membrane (Schleicher & Schuell; Whatman Group;
Keene, NH, USA) for 2 hours at 200mA on ice. Non-specific binding was blocked with
5% [w/v] non-fat dry milk in TBST buffer (0.01M Tris-HCl, 0.15M NaCl, 0.05% [v/v]
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Triton X-100, pH 8) for 1 hour at room temperature. See Appendix C for immunoblot
and zymography gel recipes. Respective primary antibodies were then added and allowed
to incubate either over night at 4°C (TIMP-1,-2, COX-1,-2) or for 1 hour at room
temperature (StAR). The membrane was then washed quickly with TBST and then 4 x 1 0
78

minutes with TBST buffer before incubation with a secondary antibody for 1 hour at
room temperature. Following a quick rinse with TBST and 4 x 1 0 minute washes, blots
were visualized using an enhanced chemiluminescent (ECL) detection system (Super^
Signal West Pico Chemiluminescent Substrate, Pierce). The blots were exposed to Kodak
XAR-5 film (Eastman Kodak Co., Rochester, NY, USA), which was developed with a
Konica (Wayne, NJ, USA) automatic developer. Two negative controls were performed
for each protein; one with either mouse or rabbit non-specific IgG in lieu of primary
antibody and the second was exclusion of the primary antibody. Details are in Appendix
D .
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Immunoblot Antibodies and Positive Controls:
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All COX antibodies and proteins were purchased from Cayman Chemical (Ann
Arbor, MI, USA). The COX-1 monoclonal antibody was raised in mice against purified
ovine COX-1 and used at a concentration of 5 ug/ml. An ovine COX-1 recombinant
protein (0.25ug) served as the positive control. The COX-2 polyclonal antibody was
raised in rabbits against a synthetic peptide from the C-terminus region of mouse COX-2
and used at 1:1000. It cross reacts with ovine, murine, and rat COX-2, but does not crossreact with COX-1 (Tsai and Wiltbank, 1997). An ovine COX-2 recombinant protein
(0.25ug) served as the positive control. The StAR polyclonal antibody (1:1000) was a
generous gift from Dr. Douglas Stocco (Texas Tech University, TX, USA). The antibody
was raised in rabbits against a synthetic peptide created from amino acids 88-98 of the
mouse StAR protein (Clarke et al., 1994). Bovine luteal tissue extract containing the 30
kDa protein was used as a positive control (Pescador et al., 1996). The TIMP-1 and -2
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primary antibodies and positive controls were purchased from EMD Biosciences (San
Diego, CA). The TEVIP-l monoclonal antibody was raised in mice against bovine TIMP1 and was used at a concentration of 1 ug/ml. The TEVIP-2 monoclonal antibody was
raised in mice against human TEVTP-2 and was used in a concentration of 5 ug/ml.
Furthermore, recombinant bovine TEVIP-l or human TIMP-2 protein standards were
included where appropriate. The secondary antibodies were immunoglobulin G
conjugated to horseradish peroxidase (Pierce, Rockford, IL, USA). Anti-rabbit secondary
antibody (1:10,000) was used for COX-2 and StAR immunoblots while anti-mouse
(1:10,000) was used for COX-1, TIMP-2, and TIMP-2 immunoblots:

Gelatin Zymography:
Gelatin zymography was used to detect gelatinase (MMP-2 and -9) activities
using previously described methods (Towle et al., 2002) with minor modifications. Luteal
extracts were mixed 1:1 with sample buffer (10% SDS, 4% sucrose [w/v], 0.1%
Bromophenol Blue [w/v], 0.25M Tris, ph 6.8) and electrophoresed under non-reducing
conditions at 200 volts using the Mini-Protean system III (Bio-Rad, Melville, NY, USA)
in 10% polyacrylamide gels containing 0.05% gelatin. Gels were then washed twice (15
minutes each) in 2.5% Triton X-100 (v/v) to remove SDS, rinsed with distilled water, and
incubated for 1.7-18 hours at 37°C in substrate buffer (5mM CaCl2, 50 mM Tris, pH 8.0).
After incubation, gels were stained with Coomassie Blue R-250 solution (0.5% in a 1:3:6
ratio of acetic acid:isopropanol:distilled water; Fischer Scientific, Fair Lawn, NJ, USA)
for 30 minutes and destained with distilled water for 1 day. Matrix metalloproteinase
activity was observed as zone (bands) of clearance against the blue background of the
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gel. Adjacent lanes contained Perfect Protein Markers (Novagen, Madison, WI, USA),
and the positive control, which is conditioned medium of the human fibrosarcoma cell
line, HT-1080 (American Culture Type Collection; Manassas, VA, USA), that is known
to produce several MMPs (e.g. MMP-2 and -9) as well as TIMPs (e.g. TIMP-1 and -2).
Details are in Appendix E.
To verify that the bands of clearing were the result of metal-dependent proteinases
(MMPs), gels were incubated in substrate buffer containing 1,10-phenanthroline (lOmM;
Sigma, St. Louis, MO). Latent and active forms of the MMPs were distinguished by
incubating the samples with 2mM p-aminophenylmercuric acetate (APMA; Sigma; St.
Louis, MO) for 2 hours prior to electrophoresis. To ensure equal sample loading, gels
containing equal volumes of sample were stained with Coomassie Blue,R-250 solution
(0.5% in a 1:3:6 ratio of acetic acid:isopropanol:distilled water; Fischer Scientific, Fair
Lawn, NJ, USA) for 30 minutes and destained with distilled water for 1 day.

Radioimmunoassay for Progesterone:
Sheep jugular blood samples were spun in a centrifuge for 25 minutes at 2500 x g
at 4°C, the plasma separated immediately, and stored at -20°C. Plasma P4 concentrations
were determined after extraction with petroleum ether (Appendix F) by
radioimmunoassay (Appendix G; Beal et al., 1980; Goldberg et al., 1996). The P4
antibody used was diluted to a final concentration of 1:10,000 (no. 337, antiprogesterone- 11-BSA; Gordon Niswender, Colorado State, Fort Collins, CO).
Radiolabeled P4 (3H-P4) was obtained from Perkin Elmer Life Sciences, Boston, Mass.
None radiolabeled P4 was purchased from Steraloids, Wilton, NH.
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Quantification and Statistical Analysis:
Photographic films of immunoblots and zymograms were densitized using UNSCAN-IT version 6.1 (Silk Scientific Industries, Orem, UT,,USA). For proteins, pixel
densities of every sample at each time point for individual sheep were determined and
averaged. Differences in means were determined using analysis of variance (ANOVA)
followed by a p-diff test using the MIXED procedure of SAS (Release 9.1). A value of
p<0.05 was considered to be significant. For steroid hormone data, P4 concentrations for
each time point were averaged and differences between mean concentrations was
determined using the Repeated Measures analysis using the Mixed Procedure of SAS
(Release 9.1). A value of p<0.05 was considered to be significant.
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Results
Analysis of Progesterone and StAR:
Prior to and following the third infusion of PGF2a, progesterone concentrations
decreased (p<0.05) by 40%, 30%, and 50% at the -1 hr, 1 hr, and 8 hr time points,
respectively, compared to the controls (Figure 13). It subsequently reached a nadir
(decreased by 75%; p<0.05) between the 8 and 16 hr time points before returning to pretreatment concentrations at 24 hrs. The standard error of the mean was determined for
each timepoint (APPENDIX I). Individual profiles of P4 concentrations in sheep that
underwent luteectomy at 24 hrs following three infusions of PGF2« are shown (Figure
14). While progesterone concentrations of sheep 1, 3, and 4 rebounded, those of sheep 2
did not. The same effect is seen when the progesterone concentration of sheep 2 is
compared to the mean progesterone concentration of sheep 1, 3, and 4 (APPENDIX J).
Immunoblotting revealed a band with a relative molecular mass of -29 kDa,
which co-migrated with the previously characterized StAR protein present in bovine
corpus luteum (Figure 15; Pescador et al., 1996). The expression of StAR decreased
(p<0.05) by 60% at the 16 hr time point and decreased (p<0.05) by 45% at the 24 hr time
point when compared to untreated control (Figure 15). To confirm that there was equal
loading of samples, /3-actin expression (Figure 16) and total protein concentrations
(Figure 40) were determined. When StAR pixel values were divided by their respective
/3-actin pixel values or by their respective total protein concentrations and then expressed
relative to the untreated (0 hr) samples, the same decrease in StAR expression at the 16
and 24 hr time points was observed (Figures 17 & 18). Also, immunoblots containing
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luteal extracts were incubated with goat anti-rabbit secondary antibody without prior
incubation with primary antibody to serve as a negative control (Figure 19). Other
immunoblots containing luteal extracts were incubated with IgG (same isotype as StAR
antibody) in lieu of StAR primary antibody, before incubation with goat anti-rabbit
secondary antibody as another negative control (Figure 20). No. bands corresponding
with the relative molecular mass of StAR were detected in either negative control.

Figure 13:
Progesterone
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Figure 13: Mean sheep jugularvein plasma P4 concentrations (ng/ml). The first (1st)
second, (2nd), and third (3rd) systemic infusions of PGF2a are indicated at the top by
bracketed arrows. The x-axis represents hours after the onset of the first infusion of
PGF2ft. Triangles (A) indicate time of luteectomy (n=4 sheep per luteectomy) relative to
the third infusion of PGFaa. Asterisks indicate significance at p<0.05.
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Figure 14:
Progesterone Concentrations of 24 Hour Luteectomy Sheep

Figure 14: Individual sheep jugular vein plasma P4 concentrations (ng/ml). The first (1st)
second, (2nd), and third (3rd) systemic infusions of PGF2tt are indicated at the top by
bracketed arrows. The x-axis represents hours after the onset of the first infusion of
PGF2a.
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Figure 15:
StAR Expression
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Figure 15: Representative immunoblot and densitometric analysis of StAR from sheep
corpora lutea extracts. Time points are 0 hr (untreated samples), -1 hr (one hour before
third infusion of PGF2a) and 1, 8,16, 24 hrs (after third infusion of PGF2a). Aliquot size
of tissue extracts is 5 ul. The arrows on the left of the immunoblot represent the
,
molecular weight markers (kDa). The arrow on the right indicates the relative molecular
mass of StAR (-29 kDa). Steroidogenic acute regulatory protein from corpora lutea
samples co-migrated with the positive control (bStAR from day 12 CL, Lane 7). All
samples are expressed as a % of untreated (0 hr) control. Asterisks indicate significance
atp<0.05.
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Figure 16:

,

ff-Actin Expression
Olu

-liu

lkr

Shi

161n

24111

50kDa->
••••••:---•••-

:

-

?«-42.kDa

37kDa-»
Figure 16: Representative immunoblot of/3-actin from sheep luteal extracts. Arrows on
the left indicate molecular weight markers (kDa). Time points are 0 hr (untreated
samples), -1 hr (one hour before third infusion PGF2a) and 1, 8, 16, 24 hrs (after third
infusion PGF2«). Volume loaded in each lane is 0.2ul. The arrow on the right indicates
the relative molecular mass of i8-actin (-42 kDa).
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Figure 17:

StAR Expression over ff-Actin
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Figure 17: The ratio of StAR over /3-Actin pixel values expressed as a % of the untreated
(0 hr) samples. Time points are 0 hr (untreated samples), -1 hr (one hour before third
infusion of PGF2a) and 1,8, 16, 24 hrs (after third infusion of PGF2Q); n = 4 for each time
point. Asterisks indicate significance at p<0.05.
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Figure 18:

StAR Expression over Total Protein
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Figure 18: The ratio of StAR over total protein concentrations expressed as a % of the
untreated (0 hr) samples. Time points are 0 hr (untreated samples), -1 hr (one hour before
third infusion of PGF2a) and 1, 8,16, 24 hrs (after third infusion of PGF2a); n = 4 for each
time point. Asterisks indicate significance at p<0.05.
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Figure 19:
Goat Anti-Rabbit Secondary Antibody
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Figure 19: Negative control blot for StAR. Arrows on the left indicate molecular weight
markers. Five microliters of corpora lutea extracts (0, -1, 1, 8, 16, 24 hrs) were loaded.
Lane 7 was loaded with 10 ul of StAR positive control (bStAR; day 12 bovine corpora
lutea extract). The membrane was incubated with goat anti-rabbit secondary antibody
without prior incubation with primary antibody. The arrow on the right indicates where
the -29 kDa StAR protein would have migrated.

Figure20:
Rabbit IgG Primary Antibody
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Figure 20: Representative negative control blot for StAR. Arrows on the left indicate
molecular weight markers. Ten microliters of corpora lutea extracts (0,-1, 1, 16, 24 hrs),
were loaded, while lane 6 was loaded with 10 ul of StAR positive control (bStAR, day 12
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bovine corpora lutea extract). The membrane was incubated overnight with normal serum
containing the same isotype, IgG, as the rabbit primary antibody prior to incubation with
the goat anti-rabbit secondary antibody. The arrow on the right indicates where the -29
kDa StAR protein would have migrated.

Expression of StAR and Progesterone Concentrations during the First Three
Infusions of PGF2r>:
We previously determined the expression of StAR and P4 concentrations
following one and two infusions of PGF2tt(Towle et al., 2002; Allen, UNH Master's
Thesis; Ricketts, UNH Master's Thesis), respectively. The data from these experiments
are integrated with those from the present study in Figure 21. Data are expressed relative
to the untreated (0 hr) samples. Progesterone concentration decreased (p<0.05) 8 hours
after the first infusion of PGF2a and did not return to control concentrations until 24 hours
after the third infusion of PGF2tt. The expression of StAR was unchanged (p>0.05) over
the first two infusions of PGF2a before decreasing (p<0.05) 16 and 24 hours after the
third infusion.
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Figure 21:
StAR and Progesterone Expression After 3 Infusions of PGF?„
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Figure 21: Expression of StAR and progesterone concentrations following three
infusions of PGF20;. All samples are expressed as a % of untreated (0 hr) control. Time is
relative to the first infusion of PGF2tt. Triangles (A) indicate time of luteectomy (n=4
sheep per luteectomy) relative to the third infusion of PGF2a. Asterisks indicate
significance at p<0.05.

Analysis of Matrix Metalloproteinase -2 and -9 (MMP-2 and -9):
Three major enzyme bands migrating at approximately 84, 72 and 64 kDa were
identified in all luteal tissue extracts by gelatin zymography (Figure 22). Representative
luteal extract samples incubated with 1,10-phenanthroline, a chelator of divalent cations
(Figure 23), revealed no zones of clearing. This confirmed that the observed enzyme
bands were due to true MMP activity (Figure 22). Also, all three enzyme species comigrated with those present in the positive control, which, was conditioned medium from
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the fibrosarcoma cell line, HT-1080. Furthermore, incubation of representative luteal
extract samples with amino phenylmercuric acetate (APMA) distinguished between
active and latent forms of these enzymes (Figure 24). The presence of APMA stimulates
cleavage of latent enzymes, yielding active, lower weight forms. Therefore, the -84 kDa
enzyme species is an active form of MMP-9, while the -72 kDa and -64 kDa enzyme
species are the latent and active forms of MMP-2, respectively. Expression of MMP-9
(-84 kDa) and MMP-2 (^72 and 64 kDa) remained unchanged (p>0.05) relative to the
untreated control, at all time points, following the third infusion of PGF2a. (Figure 22).
To further confirm that there was equal loading of samples, Coomassie Blue stained gels
were performed (Figure 25). When pixel values for each MMP were divided by their
respective Coomassie Blue pixel values and then expressed relative to the untreated (0 hr)
samples (Figure 26), the expression of MMP-2 and -9 remained unchanged.
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Figure 22:
MMP-2 and -9 Expression
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Figure 22: Representative zymogram and densitometric analysis of MMP-2 and -9 from
sheep corpora lutea extracts. Time points are 0 hr (untreated), -1 hr (one hour before third
infusion of PGF2K) and 1, 8,16,24 hrs (after third infusion of PGF2«); n = 4 for each time
point Arrows on the left of the zymogram indicate molecular weight markers (kDa).
Aliquot size of tissue extract is 1 ul. The arrows on the right indicate the relative
molecular mass of active (A) MMP-9 (-84 kDa), latent (L) MMP-2 (-72 kDa), and
active MMP-2 (-64 kDa). Each MMP species co-migrated with those present in the
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positive control, HT1080 conditioned medium. All time points are expressed as a % of
the untreated (0 hr) control.

Figure 23:
1,10-Phenanthroline
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Figure 23: Zymogram of sheep luteal extracts incubated with 1,10-phenanthroline.
Arrows on the left indicate molecular weight markers (kDa). Time points are 0 hr .
(untreated samples), -1 hr (one hour before third infusion of PGF2Q) and 1, 8, 16, 24 hrs
(after third infusion of PGF2«). The arrows on the right indicate where active MMP-9 (92
kDa), latent MMP-2 (72 kDa), and active MMP-2 (64 kDa) would have migrated. ,

Figure 24:
Amino Phenylmercuric Acetate
HT1080

100 kDa-^

MMP-9
-84 kDa A

75kDa_»
RJDMP-2
-~2\<DaL
-64 kDa A

50kD»-^ •lliili

t

Figure 24: Amino phenylmercuric acetate (ABMA). Arrows on the left indicate
molecular weight markers (kDa). Sheep CL extracts treated with (+) or without (-)
APMA were loaded. Conditioned medium from HT1080 cells was loaded in lane 7. All
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lanes show active MMP-9 (-84 kDa), latent MMP-2 (-72 kDa), and active MMP-2 (-64
kDa) co-migrating with the positive control (HT1080). Samples treated with (+) APMA
yielded an additional band (*), representing the -68 kDa species of active MMP-2.

Figure 25:
Coomassie Blue
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Figure 25: Representative gel of sheep luteal extracts stained with Coomassie Blue.
Arrows on the left indicate molecular weight markers (kDa). Time points are 0 hr
(untreated samples), -1 hr (one hour before third infusion PGF2a) and 1, 8,16, 24 hrs
(after third infusion PGF2a). Volume loaded in each lane is lul. The arrow on the right
indicates the band (-55 kDa) used for densitometric analysis.

96

Figure 26:

MMP-2 and -9 Expression over Coomassie
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Figure 26: The ratio of each MMP over Coomassie Blue pixel values expressed as a %
of the untreated (0 hr) samples. Time points are 0 hr (untreated samples), -1 hr (one hour
before third infusion of PGF2a) and 1, 8,16, 24 hrs (after third infusion of PGF2Q;); n = 4
for each time point.
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Analysis of Tissue Inhibitor of MetaUoproteinase-1 and -2 (TIMP-1 and -2):
Immunoblotting of luteal extracts revealed a protein of-29 kDa, which comigrated with the recombinant bovine TIMP-1 positive control (Figure 27). Tissue
inhibitor of metalloproteinase-1 expression decreased (p<0.05) by 20% one hour before (1 hr) the third PGF2a infusion, and decreased (p<0.05) by 30% one hour after (.1 hr) the
third PGF2« infusion, when compared to untreated controls (Ohr). When TIMP-1 pixel
values were expressed over /3-actin (Figure 29) or total protein (Figure 30) to confirm
equal loading and then expressed as a percent of the untreated (0 hr) samples, the same
changes in expression pattern were observed. In addition, a second protein of-19 kDa,
which co-migrated with the human TIMP-2 positive control (Figure 28), was also
detected. Unlike TIMP-1, there was no change (p>0.05) in TIMP-2 expression at any of
the time points. When TIMP-2 pixel values were expressed over /3-actin (Figure 29) or
total protein (Figure 30) to confirm equal loading and then expressed as a percent of the
untreated (0 hr) samples, no changes (p>0.05) were observed at any time point. As
negative controls, additional membranes containing luteal extracts were incubated with
goat anti-mouse secondary antibody without prior incubation with the respective primary
antibodies for TIMP-1 and -2 (Figure 31), or they were incubated with mouse IgGi (same
isotype as TIMP-1 and -2 antibodies) in lieu of TIMP-1 or TIMP-2 primary antibody,
before incubation with goat anti-mouse secondary (Figure 32). No bands corresponding
to the relative molecular masses of TIMP-1 or TIMP-2 were detected on any of the
negative control membranes.
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Figure 27:
TIMP-1 Expression
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Figure 27: Representative immunoblot and densitometric analysis of TIMP-1 from sheep
corpora lutea extracts. Time points are 0 hr (untreated), -1 hr (one hour before third
infusion of PGF2tt) and 1, 8, 16, 24 hrs (after third infusion of PGF2tt). Aliquot size of
tissue extract was 2 ul. The arrow on the left indicates the molecular weight marker
(kDa). The arrow on the right indicates the relative molecular mass of TIMP-1 (~29
kDa). Tissue inhibitor of metalloproteinase-1 from corpora lutea extracts co-migrated
with the positive control, bovine TIMP-1 (bTIMP-1, Lane 7). All time points are
expressed as a % of untreated (0 hr) control Asterisks indicate significance at p<0.05.
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Figure 28:
TIMP-2 Expression
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Figure 28: Representative immunoblot and densitometric analysis of TIMP-2 from sheep
corpora lutea extracts. Time points are 0 hr (untreated), -1 hr (one hour before third
infusion of PGF2Q) and 1, 8, 16, 24 hrs (after third infusion of PGF2a). Aliquot size of
tissue extracts is 10 ul. The arrows on the left indicate the molecular weight markers
(kDa). The arrow on the right indicates the relative molecular mass of TIMP-2 (-19
kDa). Tissue inhibitor of metalloproteinase-2 from corpora lutea extracts co-migrated
with the positive control, human TIMP-2 (hTIMP-2, Lane 7). All samples are expressed
as a % of untreated (0 hr) control.
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Figure 29:

TIMP-1 and -2 Expression over ff-Actin
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Figure 29: The ratio of TIMP-1 and -2 over /3-Actin pixel values expressed as a % of the
untreated (0 hr) samples. Time points are 0 hr (untreated samples), -1 hr (one hour before
third infusion of PGF2a) and 1,8, 16, 24 hrs (after third infusion of PGF2a); n = 4 for each
time point. Asterisks indicate significance at p<0.05.
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Figure 30:

TIMP-1 and -2 Expression over Total Protein
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Figure 30: The ratio of TIMP-1 and -2 over total protein concentrations expressed as a %
of the untreated (0 hr) samples. Time points are 0 hr (untreated samples), -1 hr (one hour
before third infusion of PGF2a) and 1, 8, 16, 24 hrs (after third infusion of PGF2tt); n = 4
for each time point. Asterisks indicate significance at p<0.05.
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Figure 31:
Goat Anti-Mouse Secondary Antibody
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Figure 31: Representative negative control blot for TIMP-1 and TEVIP -2. Arrows on the
left indicate molecular weight markers. Aliquots (2 ul and 10 ul) of corpora lutea extracts
are indicated. The membrane was incubated in the absence of primary antibody, but
instead was incubated only in the presence of the goat anti-mouse secondary antibody.
The arrows on the right indicate where the -29 kDa TIMP-1 and -19 kDa TEVIP-2
. proteins would have migrated.

Figure 32:
Mouse l e d Primary Antibody
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Figure 32: Representative negative control blot for TIMP-1 and TIMP-2. Arrows on the
left indicate molecular weight markers. Aliquots (2 ul and 10 ul) of corpora lutea extracts
are indicated. The membrane was incubated overnight with normal serum containing the
same isotype, IgGi, as the mouse primary antibody, before incubation with goat anti103

mouse secondary antibody. The arrows on the right indicate where the -29 kDa TIMP-1
and-19 kDaTIMP-2 proteins would have migrated.

Expression of MMPs and TIMPs during the First Three Infusions of PGF^;
We previously determined the expression of MMP-2 and -9 and TIMP-1 and -2
following one and two infusions of PGF2a(Towle et al., 2002; Ricketts, UNH Master's
Thesis), respectively. The data from these two experiments along with data from the
present experiment (third infusion) are graphed in Figure 33 to profile the expression
patterns of MMPs and TIMPs throughout the first three infusions of PGF2a. Data are
expressedrelative to untreated (0 hr) samples. Expression of MMP-2 and -9 did not
change (p>0.05). However, TIMP-1 decreased (p<0.05) 1 hour after each infusion of
PGF2« while TEVIP-2 decreased (p<0.05) 1 hour after the first infusion and remained
decreased (p<0.05) until 1 hour after the second infusion before returning to pretreatment levels. The ratio of MMPs:TEVIPs throughout the first three infusions of PGF2a
are depicted in Figure 34, When expressed as a ratio,/active MMP-2:TEVIP-2 and active
MMP-9:TIMP-1 increased after the first and second infusion of PGF2a before returning to
the level similar to the control (0 hr) ratio following the third infusion.
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Figure 33:
MMP and TIMP Expression Following Three Infusions of PGF7„

Figure 33: Expression of MMPs and TIMPs following three infusions of PGF2«. All
samples are expressed as a % of untreated (0 hr) control Time is relative to the first
infusion of PGF2a. Asterisks indicate significance at p<0.05.
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Figure 34:

MMP/TIMP Ratio Following Three Infusions of PGF^
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Figure 34: The ratio of active MMP-2 (MMP-2 A) over TIMP-2 and MMP-9 (MMP-9
A) over TIMP-1 following three infusions of PGF2a. The first (1st) second, 2nd), and third
(3rd) systemic infusions of PGF2a are indicated at the top by bracketed arrows.

Analysis of COX-1 and COX-2:
While immunoblotting detected the ovine COX-1 positive control migrating at
-70 kDa (Figure 35), no corresponding-bands were detected in any of the lanes
containing luteal extracts. In contrast, immunoblotting of luteal extracts revealed a
protein of-72 kDa, which co-migrated with the ovine COX-2 positive control (Figure 36
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A). Densitometric analysis showed no changes (p>0.05) in COX-2 expression following
three infusions of PGF2a (Figure 36 B). When COX-2 pixel values were divided by their
respective jS-actin pixel values to confirm equal loading, the expression pattern remained
the same (Figure 37). When the first immunoblot was excluded in the analysis, there was
a 300% increase (p<0.05) in COX-2 expression at the -1 and 8 hr time points (Figure
38). In turn, when COX-2 pixel values were divided by their respective /3-actin pixel
values to confirm equal loading, the same increase was observed (Figure 39).
Figure 35:
COX-1 Expression
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Figure 35: Representative immunoblot of COX-1 from sheep luteal tissue extracts. Time
points are 0 hr (untreated), -1 hr (one hour before third infusion of PGF2a) and 1, 8,16,
24 hrs (after third infusion of PGF2Q). Aliquot size of tissue extracts is 20 ul. The arrows
on the left indicate the molecular weight markers (kDa). The arrow on the right indicates
the relative molecular mass of COX-1 (-70 kDa). Tissue extracts are in lanes 1-6 while
the positive control, ovine COX-1, is in lane 7.
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Figure 36 A.
COX-2 Immunoblots
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Figure 36 A: All four COX-2 immunoblot^ of sheep corpora lutea extracts. Time points
are 0 hr (untreated samples), -1 hr (one hour before third infusion of PGF2tt) and 1, 8,16,
24 hrs (after third infusion of PGF2a). Aliquot size of tissue extract is 15 ul. The arrow on
the left indicates the molecular weight markers (kDa). The arrow on the right indicates
the relative molecular mass of COX-2 (-72 kDa). Cyclooxygenase-2 from samples comigrated with the positive control, ovine COX-2 (oCOX-2, Lane 7).
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Figure 36 B.
COX-2 Expression
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Figure 36 B: Densitometric analysis of COX-2 from sheep corpora lutea extracts. Time
points are 0 hr (untreated samples), -1 hr (one hour before third infusion of PGF2a) and 1,
8, 16, 24 hrs (after third infusion of PGF2a)- All,time points are expressed as a % of
untreated (0 hr) samples.
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Figure 37:

COX-2 Expression over /3-Actin
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Figure 37: The ratio of COX -2 over /3-actin pixel values expressed as a % of the
untreated (0 hr) samples! Time points are 0 hr (untreated samples), -1 hr (one hour before
third infusion of PGF2a) and 1,8, 16, 24 hrs (after third infusion of PGF2Q); n = 4 for each
time point.
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Figure 38:

COX-2 Expression (Gels 2,3, & 4)
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Figure 38: Densitometric analysis of COX-2 from sheep corpora lutea extracts (Gels 2,
3, &4) Time points are 0 hr (untreated), -1 hr (one hour before third infusion of PGF^a)
and 1, 8,16, 24 hrs (after third infusion of PGF2«). All time points are expressed as a %
of untreated (Ohr) control. Asterisks indicate significance at p<0.05.
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Figure 39:

COX-2 Expression (Gels 2,3, & 4) over ff-actin

500

*

iJ 400
Q.

E
(0
w
.c 300 H
o

*

r^n

!
i

.

1

sS 100-

-L

<

i

i

S 200
c

i—i

*•*

I.

Q>

j

!

i
"
i

i

0

-1

1

8

16

24

Time (Hours Relative to Third Infusion of PGF2a)
Figure 39: The ratio of COX-2 (Gels 2, 3, and 4) over |S-actin pixel values expressed as a
% of the untreated (0 hr) samples. Time points are 0 hr (untreated samples), -1 hr (one
hour before third infusion of PGF2Q) and 1,8,16, 24 hrs (after third infusion of PGF2a); n
= 3 for each time pbint. Asterisks indicate significance at p<0.05.

Bradford Assay:
Total protein concentrations were determined for each corpora lutea extract
(Figure 40), using the Bradford Assay standard curve (Figure 41), to further confirm
equal loading in zymograms and immunoblots. There were no differences in total protein
concentrations between any of the time points (p>0.05).
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Figure 40:
Bradford Assay
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Figure 40: Total protein concentrations of corpora lutea extracts determined by Bradford
Assay. Each number represents the mean of duplicate samples from untreated (0 hr) CL,
and from those removed -1 hr (one hour before third infusion of PGF2a) and 1, 8,16, and
24 hrs (after the third infusion of PGF2«; n = 4 for each time point).

Figure 4.1':
Bradford Assay Standard Curve
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Figure 41: Bradford Assay standard curve. Line of best fit (y = 0.0434,x + 0.0187) and R
(0.9977) values are shown.
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DISCUSSION
Luteolysis encompasses two events, functional regression as well as structural
regression of the corpus luteum, but their timing may be asynchronized (Juengel et al.,
1993; McGuire et al, 1994; Tian et al., 1994). Therefore, we developed a model that
allows us to determine the changes in P4 concentration, and StAR, MMP, TIMP and
COX protein expression, in response to multiple physiological infusions of PGF2a that
mimic the natural frequency in sheep. As a result, we can profile the temporal expression
patterns of these endpoints to better understand the relationship between the functional
and structural regression of the CL during luteolysis.
Functional regression of the CL is typified by a decline in plasma P4
concentration (Hoyer, 1998; Stocco et al., 2007). In the current study, while plasma P4
concentrations declined between 40 and 75% following the first three infusions of PGF2o,
they nonetheless rebounded to pre-infusion levels (Figure 13). However, looking at the
data in more detail revealed that the P4 concentration in one of the four sheep remained
low and did not rebound (Figure 14), suggesting that the CL was probably undergoing
irreversible functional regression. Interestingly, the pattern of StAR expression did not
mirror P4 concentrations, i.e. StAR protein expression decreased by 60 and 45% 16. arid
24 hours, respectively, following the third infusion of PGF2a (Figure 15), whereas no
change in StAR was observed following the first or second infusion of PGF2a (Figure
21). Notably, the expression of StAR in the sheep whose P4 concentrations never
rebounded was 55% less than the other three animals, further supporting that irreversible
functional regression of the CL was probably occurring in this animal. In this one sheep,
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the P4 concentration and StAR expression results are consistent with our previous finding
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that 33% of sheep undergo complete luteolysis following three infusions of PGF2a
(McCracken et al., 1999). The fact that P4 concentrations decreased well before the
decline in StAR expression (Figure 21) may be explained by the decrease in membrane
fluidity observed during luteolysis (Goodsaid-Zalduondo et al, 1982; Carlson et al.,
1984; Luborsky et al., 1984). The reduced membrane fluidity may prevent LH receptor
aggregation decreasing the amount of active hormone sensitive lipase, the enzyme
responsible for cleaving cholesterol from lipid droplets. Another possibility is that PGF2Qdecreases the expression of sterol carrier protein-2 (SCP-2), 3/3-HSD and P450scc
(McLean et al., 1995). Sterol carrier protein-2 transports cholesterol to mitochondria and
decreases 8 hours following PGF2a treatment in rats. Similarly, a decline in 3/3-HSD and
P450scc is seen 4 hours after PGF2« treatment. Thus the decline in P4 before the decrease
in StAR expression (Figure 21) may be explained by the decrease in SCP-2, 3/3-HSD and
P450scc. Further, ovarian blood flow following PGF may also play a role. The
relationship between blood flow and P4 concentrations after PGF2a was also considered
(Einer-Jensen and McCracken, 1981; Ginther, 2007). Perhaps reduced ovarian blood
flow, in response to PGF2a, decreases peripheral P4 concentrations. However, P4
concentrations decrease in sheep (Einer-Jensen and McCracken, 1981) and mares
(Ginther, 2007) before any change in capillary blood flow in the ovary was observed. In
contrast, Acosta et al. (2002) found that intraluteal blood flow within a midcycle CL
increased 0.5 hours, but then decreased 4 and 8 hours after 500ug PGF2tt treatment. In a
later study, Acosta et al. (2008) found that peripheral P4 concentrations also decreased in
the midcycle CL 4 hours following the same treatement of PGF2a. Although StAR
expression was not reported, the above studies suggest that the relationship between P4
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concentrations and StAR is complex. Overall, additional studies are needed to elucidate
the mechanisms behind the temporal asynchrony between peripheral P4 concentrations
and StAR protein expression following PGF.
Structural regression of the CL is mediated, in part, by degradation of the ECM,
the result of net MMP activity (Endo et al., 1993; Liu K et al., 1999; Xinlei et al., 2006;
i
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Kliem et al., 2007). We previously reported an increase in active MMP-2 following one
and two infusions of PGF2Q: (Towle et al., 2002; Rickets, UNH Master's Thesis). In order
to compare MMP expression between experiments in sheep that received one, two or
three infusions of PGF2tt, all time points within each experiment were expressed as a
percent of the control (untreated) samples. Upon doing so, no changes in gelatinase
activity were revealed (Figure 33). This is consistent with the fact that MMP-2 is
expressed constitutively in most tissues (Salo et al., 1985; Templetone et al., 1990;
Huhtala et al., 1991; Yeow et al., 2001), although it can be moderately induced 2-4 fold
(Huhtala et al., 1991; Overall et al., 1991; Salo et al, 1991) while MMP-9 can be induced
8 fold (Salo et al., 1991; Overall et al., 1.991). It is possible that the differences in
gelatinase expression using our physiological model in sheep and approaches used by
others may be attributed to variations in dose and frequency of PGF2a. The active MMP2, latent MMP-2 and active MMP-9 expression in the sheep that appeared to undergo
irreversible functional regression was 10, 20, and 25 % greater, respectively, than the
other three sheep in that time point. This suggests that net proteolysis may have occurred
in this animal; however, TIMP expression needs to be considered.
Tissue inhibitors of metalloproteinases aid in regulating the structural degradation
of the luteal ECM by inhibiting MMPs (Mclntush and Smith, 1999; Ricke et al, 2002c;

Zhang et al., 2003; Kliem et al, 2007). In the present study, TIMP-1 decreased by 20 and
30% 1 hour before (-1 hr) and 1 hour after (1 hr) the third infusion of PGF2a, respectively
(Figure 27), which is similar to the decrease in TEMP-1 protein seen after the first and
second infusions (Figure 33) and after a single luteolytic dose of PGF 2 Q ; administered to
sheep (Mclntush and Smith, 1997). In addition, several studies also report a decrease in
TEVIP-1 expression during natural or PGF2a induced luteolysis (Inderdeo et al., 1996;
Ricke et al., 2002c; Young et al., 2002; Xinlei et al., 2006; Kliem et al, 2007) or in the
late-stage CL (Zhang et al., 2003). On the other hand, TIMP-2 expression was unchanged
after three infusions of PGF2tt (Figures 28), in contrast to the decrease observed
following the first and second infusions (Figure 33). During natural luteolysis in several
species, TIMP-2 expression either increases (Pitzel et al., 2000; Young et al., 2002;
Zhang et al., 2003; Xinlei et al., 2006) or is unchanged after PGF2Q treatment (Nothnick
et al., 1995; Ricke et al., 2002c). However, Smith et al. (1995) reported that TIMP-2
mRNA decreases in the sheep corpus luteum from early luteal phase (days 3-7) to late
luteal phase (day 16). This decrease in TIMP-2 mRNA occurs about 48 hours (day 16)
after the first physiological pulse of PGF2« (day 14). Therefore, it may take 48 hours
following the first infusion of PGF2« in our study to see a second decrease in TIMP-2
protein, which might explain why TIMP-2 returned to control (0 hr) concentrations after
three infusions of PGF2a. This suggests that TIMP-2 protein expression might not
decrease again until after additional pulses of PGF2«. Further, the individual expression of
MMPs or TEVIPs may reveal the full picture. Instead, the balance between MMP activity
and TIMP expression need to be considered. The unchanged expression of MMP-2 and 9 accompanied by the decrease in TIMP-1 and -2 during the early onset of luteolysis
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(Figure 33) may result in net proteolytic activity; however, histological staining of EGM
components is needed to strengthen this conclusion. After the third infusion of PGF2a,
TEVIP-1 and -2 expression returned to pretreatment levels while MMP activity was
unchanged. Thus, the balance between MMPs and TEVIPs was restored (Figures 33 &
34), suggesting that the structural integrity of the CL is maintained after three infusions
of PGF2o:. It is worth noting that the TIMP-2 pixel value for the sheep whose P4
concentrations never returned to control concentrations was 70% lower than that of the
other three sheep at the 24 hour time point (but TIMP-1 was not different). With the
preference of TIMP-2 for MMP-2, this sizable decrease in TIMP-2 expression in this
animal may result in structural regression of the CL. However, experiments with sheep
receiving additional pulses of PGF2a, along with histological staining of the CL for ECM
degradation and evidence of DNA fragmentation and apoptosis would need to be
performed to confirm structural regression. Furthermore, it is also important to keep in
mind that other MMPs, such as MMP-1, 14, and 19, and other TIMPs, such as TIMP-3
and TIMP-4, may also play a role in structural regression of the CL (Chen et al„ 2006;
Kliem et al., 2007).
Luteolysis is initially driven by pulses of uterine PGF2ain sheep (McCracken et
al., 1972; Zarco, 1988), which subsequently induces production of luteal PGF2« (Rexroad
and Guthrie, 1979; Tsai and Wiltbank, 1997). In the present study, luteal COX-1 was not
detected after three infusions of PGF2a (Figure 35), which is consistent with our previous
findings following one and two infusions (Allen, UNH Master's Thesis; Ricketts, UNH
Master's Thesis). These results are not surprising because COX-1, the non-inducible
isoform, is constitutively expressed in relatively small amounts in most tissues, including
' . -' •
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the CL (Smith et al., 2000; Arosh et al., 2004). In contrast, the COX-2 isoform is
inducible (Lafyatis et al., 1989; Lin et al, 1989; Smith et al., 1994). Following three
infusions of PGF2tt, luteal COX-2 expression remained unchanged (Figure 36 B), which
is in contrast to the 300% increase we previously observed in response to one and two
infusions of PGF2a (Allen, Ricketts, Master's Thesis). However, if immunoblot 1 is
excluded (because of unexplainable technical issues; it is inconsistent with the remaining
immunoblots), COX-2 increases by 300% at the -1 hr and the 8 hr time points (Figure
38), which is similar to the increase in magnitude seen after one and two infusions of
PGF2a (Allen, Ricketts, UNH Master's thesis) and reported by others (Tsai and
Wiltbank, 1997; Hayashi et al., 2003; Arosh et al., 2004; Zerani et al., 2007). Despite the
increase in COX-2 at the 8 hr time point following the third infusion of PGF2a (gels 2, 3,
and 4), it returns to pre-infusion concentrations at the 16 and 24 hour time points (Figure
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38). It is important to keep in mind that during physiological luteolysis, the fourth pulse
occurs 8 hours after the third. Therefore, in order for luteal COX-2 expression to remain
increased beyond the 8 hr time point, a fourth infusion may be necessary. Interestingly,
the COX-2 expression of the sheep whose P4 concentration never rebounded was 85%
lower than that of the remaining sheep at the 24 hr time point. Perhaps complete luteal
regression occurred in this animal.
m summary, throughout the first three infusions of PGFia in the sheep, it appears
that a decrease in TIMPs accompanied by unchanged MMP expression results in local
MMP activity that brings about net proteolysis. This is consistent with steps 2 and 3 of
our proposed cell model of luteolysis in sheep (Appendix H). However, our present
results also indicate that the balance between MMPs and TIMPs is restored following the
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third infusion of PGF2« suggesting that the overall structure of the CL is probably
maintained. It therefore may take four or five infusions of PGF2a to see another decrease
in TEVIP proteins and possibly an increase in MMP expression, resulting in the structural
demise of the CL. With each subsequent infusion of PGF2a, the CL is also more likely to
undergo functional decline. In response to the disruption of the ECM by MMP activity,
the integrity of integrins within luteal cells becomes compromised (Choquet et al, 1997;
Calderwood et al., 2000), cholesterol transport by StAR decreases, and as a consequence,
so does P4 secretion (Niswender et al., 2000). This is depicted in step 3 of our proposed
cell model. Furthermore, COX-2 expression increases throughout the first three infusions
of PGF2a which increases luteal PGF2a to aid in regression of the CL. In conclusion, three
sequential pulses of PGF2« are insufficient to cause the majority of sheep to undergo
luteolysis. However, based on the results from the one sheep whose P4 concentrations did
not rebound after three infusions of PGF2tt, the concomitant low expression of StAR and
TIMP-2 proteins indicates that they may be the crucial players in the functional and
structural demise of the CL. Their expression profiles, as well as other mediators of
luteolysis, following four or five infusions of PGF2Q, will ultimately reveal the interplay of
proteins that lead to regression of the CL.
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APPENDIX A. PROTEIN EXTRAXCTION FROM LUTEAL CELLS

SOLUTIONS:
Extraction Buffer:
50mMTris
ISOmMNaCI
0.02% Sodium Azide
lOmMEDTA
r
1% Triton X-100
Bring up to volume with cold ddl^O
pH to 7.4, prior to adding Triton X-100
* All steps performed on ice or at 4°C.
1. Add protease inhibitors to extraction buffer right before use:
a. lug/ml AEBSF
< b. 1 ug/ml Pepstatin A
c. 1 ug/ml Aprotinin
2. Remove tissue from freezer and weigh.
3. Add 8 ml of extraction buffer for every 1 g tissue, scissor mince. Clean polytron
probe for homogenation:
•
J
'. .
a. Rinse probe with EtOH, ddH20, and extraction buffer.
.
4. Transfer minced tissue (with extraction buffer) to glass tube.
5. Homogenize tissue at speed 9 for 30 seconds.
6. Rinse polytron probe with water, EtOH, and extraction buffer and remove any
tissue debris if necessary.
7. Repeat homogenization for each sample.
8. Centrifuge at 4°C, 10,000 x g for 10 minutes.
9. Transfer supernatant into new 1.5 ml eppendorf tube and repeat centrifuge until
no pellet forms.
10. Store at-80 6 C.
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APPENDIX B: PROTEIN DETERMINATION (BRADFORD ASSAY)
SOLUTIONS:
Phosphate Buffered Saline:
- - ' • ' • ' 0.25 M Na 2 HP0 4
0.25MNaH 2 PO 4
8.1gNaCl
Bring up to 1 L with ddH^O
pH to 7.4

.-"':

1. Set up standard curve (in duplicate) in 13 x 75 mm glass test tubes:

-

Tube#
1.2
2.3
4,5
6,7
8,9
10,11

.

BSA
0
:4ul(2ug)
8ul(4ug)
12ul(6ug)
16ul(8ug)
20ul(10ug)

PBS
800 ul
796 ul
792ul
788 ul
784 ul
780 ul

2. Set up samples (in duplicate) in 13 x 75 mm glass tubes:
Tube #.
13,14
15,16

Sample
2.5 ul
5ul

*samples diluted 1:10
*repeat for each sample
3.
4.
5.
6.

PBS
797.5 ul
795 ul

r

Quickly add 200 ul of Bio Rad Bradford Assay Reagent and vortex.
Read absoebance at 595 nm and record values
Graph standard curve (ug BSA on x-axis and absorbence on y-axis)
Using the regression equation, calculate the protein concentration (ug/ul) in each
sample.
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APPENDIX C: IMMUNOBLOTTING AND ZYMOGRAPHY
SOLUTIONS
V

Ammonium Persulfate (100 mg/ml)
200 mg Ammonium Persulfate
2mlddH 2 0

1.5 M Tris (pH 8.8)
18J7gTris
100mlddH 2 O

4 mM APMA Solution
14.1 mg aminophenylmercuric acetate
100mlddH 2 O

0.5 M Tris (pH 6.8)
6.06 g Tris
100mlddH 2 O

10 mM l,lb-Phenanthroline
435 mg 1,10-phenanthroline
200mlddH 2 O

0.25 M Tris (pH 6.8)
3.03 g Tris
100mlddH 2 Q

Stacking Gel (4% Acrylamide)
6.36 ml ddH 2 0
2.52 ml 0.5 M Tris (pH 6.8)
1 ml 40% Acrylamide
100 ul 10% SDS
50 ul Ammonium Persulfate (100 mg/ml)
lOulTEMED

Sample Buffer
10 ml 0.25 M Tris (pH 6.8)
lgSDS
400 mg sucrose
10 mg bromophenol blue

Separation Gel (10% Acrylamide)
7.5 mg gelatin
7.275 ml ddH 2 0
3.75 ml 1.5 M Tris (pH 8.8)
3.75 ml 40% Acrylamide
150ull0%SDS
75 ul Ammonium Persulfate
7.5ulTEMED

Separating Gel (12% Acrylamide)
]Sk> gelatin for Westerns
6.525 ml ddH 2 0
3,75 ml 1.5 M Tris (pH 8.8)
4.5 ml 40% Acrylamide
150 ul 10% SDS
75 ul Ammonium Persulfate
7.5ulTEMED

Electrode Buffer 1 Ox
30 g Tris
144 g Tris
5 g SDS
Bring to 1 L with ddH 2 0

Substrate Buffer
6.07 g Tris
970mg CaCl2-2H20
200 mg Sodium Azide
Bring to 1 L with ddH 2 0

(
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Coomassie Blue Stain
2.5 g Brilliant Blue R-250
50 ml Acetic Acid
150 ml Isopropynol
300mlddH 2 O '

2.5%Triton X-l00 Solution
5 ml Triton X-l00
195mlddH 2 0
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APPENDIX D: IMMUNOBLOT (WESTERN) PROCEDURE AND
SOLUTIONS
SOLUTIONS:
TEST Buffer
1.2-gTris..
/
8.8gNaCl
0.5 ml Tween 20
Bring up to 1 L withddEbO

Blotting Buffer
800mlddH 2 O
200 ml Methanol
15.03 g Glycine
3.15gTris

5% Milk
2.5 g evaporated non-fat powdered milk
50 ml TBST Buffer

-

PROCEDURES:
Part 1: Electrophoresis
1. Cast gels using recipes above:
a. Separating Gel: 12% acrylamide for TIMPs, and StAR
b. Stacking Gel: 4% acrylamide .: " 2. Use Bio Rad Precision Plus Dual Color Protein Standards for molecular
weight markers.
v.
3. Load positive controls and samples.
4. Electrophorese for ~1 hour at 200 volts-electrophoresis is the same for
zymographies.
,
-

-

Part 2: Prepare for Blotting
1. Cut four pieces of filter paper and prepare 4 pieces of blotting foam.
2. Cut nitrocellulose membranes to fit atop gel accordingly.
3. When gels are almost done running, prepare blotting buffer-add methanol last.
Let filter paper, sponges and membranes soak in blotting buffer.
4. When electrophoresis is complete, cut off stacking gel and let equilibrate in
blotting buffer. Repeat for 2nd gel.
• - : • . '
5. Put notched side of membrane on the top right.
\
Part 3: Electroblotting
1. On black side of plastic sandwich, place in order: 1 blotting sponge, 1 piece of
filter paper, gel, 1 nitrocellulose membrane, 1 piece of filter paper, 1 blotting
sponge.
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• 2. Insert sandwich into electrode cassette with black part of the sandwich facing
the black part of the electrode cassette. Place Cassette into tank with blotting
buffer.
3. When both sandwiches are in the tank, add a small stir bar and an ice pack
into the open area. Fill the tank with blotting buffer.
4. Place tank assembly into a basin filled with ice and place onto a stir plate.
Place electrode tank cover onto tank and set the power source to 200 mAmps
for 2 hours.
Part 4: Blocking
1. Before blotting is complete, make blocking buffer (5% milk).
2. Once blotting is complete, remove nitrocellulose membranes and place in 50
ml blocking silution on shaker for 1 hour.
i.

Part 5: Adding Primary Antibody
1. Before blocking is complete, thaw primary antibody and dilute to appropriate
concentration in 10 ml blocking buffer.
2. When blocking is complete, discard milk.
3. Add 5 ml of antibody to each membrane.
4. Gut 2 pieces of parafilm and place over membranes.
5. Let incubate 12-16 hours at 4°C on slow nutator.
Part 6: Washing Membranes
1. Remove the primary antibody and freeze at 20°C.
2. Rinse quickly with TBST.
3. Rinse 4 x 10 minutes with TBST.
4. During last rinse, prepare secondary antibody in 50 ml blocking solution.
Part 7: Adding Secondary Antibody
.1. Add 5 ul of secondary antibody to 50 ml blocking solution.
2. Remove TBST from membranes and add 25 ml of secondary antibody to each
membrane..- •
3. Shake on low fori hour.
_
Part 8: Second Set of Washes
• T. Remove secondary antibody and quickly rinse with TBST.
2. Rinse 4 x 1 0 minutes with TBST.
3. Turn on developer and press run after the second wash.
Part 9: Chemiluminescent Detection
1. Make Super Signal chemiluminescent solution with lights off (Pierce kit; 5 ml
of each solution).
2. When washing is complete, discard buffer and add 5 ml off Super Signal to
each membrane.
175

3. Let incubate for 5 minutes.
Part 10: Prepare membranes for Documentation
1. Place a piece of saran wrap -12 inches x ~8 inches on a flat, clean surface.
2. Using tweezers, shake excess Super Signal off onto kimwipe and place the
membrane face side down onto the saran wrap.
3. Place a piece of filter paper on top of membranes and wrap saran wrap around
the filter paper.
4. Turn over and place into film cassette. Tape down to prevent movment.
5. Bring film into dark room and expose film on membranes (exposure time
depends on presence of protein) and process film.
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APPENDIX E: GELATIN ZYMOGRAPHY PROCEDURES
DAY1:
1.
2.
3.
4.

Heat water bath to -90° C.
'
Make ammonium persulfate solution in 1.5 ml tube.
Weigh gelatin and place into 50 ml tube.
Prepare gel solution:
a. Add ddH 2 0 to tube followed by 1.5 M Tris (pH 8.8), 40% acrylamide
(wear gloves), and SDS.
b. Heat contents in hot water bath (3o sec. dips) until gelatin is completely
dissolved.
c. Let cool to room temperature.

x
J

5. Set up gel apparatus:
a. Rinse and dry all components.
b. Place rubber gasket onto tower.
c. Place 1 small and 1 large plate into green holder and tighten.
d. Secure assembly to the towers
6. Casting the separating Gel:
a. Add TEMED and APS to the gel solution and swirl to mix.
b. With Pasteur pipette, quickly load the gel solution between the two plates.
Fill up to green line.
c. With a new Pasteur pipette, add ddH20 on top of the gel solution.
d. Allow gel to polymerize (45 minutes).
7. Casting the Stacking Gel:
a. When separating gel is almost polymerized, add all the ingredients for the
stacking gel solution, except APS and TEMED.
b. Dump off water on top of separating gel and dry area with filter paper.
c. Add APS and TEMED to the stacking gel solution and swirl to mix.
d. Load the stacking gel solution on top of the separating gel.
e. Immediately insert a 1 mm thick 10 well comb into the stacking gel.
f. Allow to polymerize for 35 minutes.
8. Preparing Samples and Standards:
a. While the stacking gel is polymerizing, make up loading samples in .5 ml
tubes.
/
b. Use an equal volume of sample to sample buffer (1:1) unless otherwise
indicated.
9. Loading Samples:
a. When stacking gels are polymerized, carefully remove combs.
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b. Remove the gel/glass plate assembly and insert into electrode cassette and
place in tank.
,
c. Add 800 ml of lx electrode buffer to the center area between the gels,
making sure to gently rinse the wells of the gels.
d. Load samples
10. Running the Gels:
a. Once gels are loaded, attach electrode cover in proper orientation.
b. Plug electrode into power source and set volts to 200.
c. Run until dye reaches the bottom of the gel.
d. Prepare the Triton X-100 solution during the last 15 minutes of running.

,

11. Triton Washes:
a. Whe n the gel is finished running, remove gels from the apparatus and
place them into 150 mm Petri dishes and label.
b. Cover gels with-100 ml Triton X-100 solution and place on shaker
l
vigorously for 15 minutes.
c. Drain off Triton X-100 solution and repeat steps b-c.
d. When second wash is complete, rinse gels with ddH^O several times. 12. Fill each dish with ~150 ml of substrate buffer;
13. Place on shaker in 37°C incubator and shake gently overnight.

Day 2:
1. Staining the Gels:
- a. Remove gels form incubator and pour off substrate buffer.
b. Add 50 ml of Coomassie solution to each dish.
c. Shake gently at'room temperature for 30 minutes.
v
2. Destaining Gels:
a. Aspirate off Coomassie stain. Rinse gels several times with ddlrbO.
b. Shake gels in ddHbO at room temperature, changing water periodically,
until clear bands are visible.
c. When gels are of satisfactory intensity, take a picture of gels.
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APPENDIX F: PROGESTERONE EXTRACTION
1. Centrifuge blood samples for 20 minutes in 4°C centrifuge and save plasma.
<. 2. Take 100 ul of plasma from each sample and add 2 ml of petroleum ether.
Vortex for 60 seconds.
3. Snap freeze samples in acetone/dry ice bath for 10 seconds.
•c 4. Decant ether layer into new tube.
5. Dry \vithN2.
6. Repeat steps 2-5.
7. Rinse sides of new tubes with petroleum ether using a Pasteur pipette.
8. Reconstitute samples in 200 ul PBSG and vortex.
9. Use immediately in radioimmunoassay or freeze at -20°C.
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APPENDIX G: RADIOIMMUNOASSAY OF PROGESTERONE
SOLUTIONS:
Phosphate Buffered Saline with Gelatin (PBSG; pH 7.0)
5.38 g
16.35 g
1.0 g
9g
1g

NaH 2 P0 4 -H 2 0
Na 2 HP0 4 H 2 0
Sodium Azide
NaCl
Gelatin

1. Add all solutes to 800 ml ddH 2 0 and stir on a warm stir plate until dissolved.
2. Adjust pH to 7.0.
3. Bring volume up to 1 L with ddH 2 0. Store at 4°C for no longer than 2 weeks.
Charcoal Suspension
200 mg
20 mg

Prewashed Norit A neutral charcoal
DextranT-70

1. Add charcoal and Dextran to 100 ml of PBSG
2. Stir on ice for 30 minutes on high speed before using. Store at 4°C for no
longer than 2 weeks.
Progesterone Antibody
1. Just before using, thaw stock antibody solution (1:10).
2. Make a 1:250 dilution with PBSG for a final dilution of 1:2500. This antibody
concentration typically yields 30-50% binding.
Tritiated Progesterone
1. Pipette 30 ul of 3H-progesterone (50 uCi/ml ethanol) into a 20 ml glass vial.
2. Dry down under 37°C water bath under air.
,
3. Add 15 ml PBSG, cover, vortex, and incubate in 37°C water bath for 15
minutes. Store at 4°C.
Progesterone Standards
v
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1. Make a 1:100 dilution of stock A (800 ug/ml) to yield stock solution B (8
ug/rril). Stock solutions are dissolved in ethanol, stored at -20°C, and warmed to
room temperature before using.
2. Prepare a range of standards consisting of the following concentrations: 0.125,
0.25, 0.5, 1, 2, 4, 8, and 16 ng/ml. Add 100 ul of stock B to 4.9 ml PBSG to yield
a premix of 160 ng/ml. Add 2 ml of premix to 18 ml PBSG to yield a 16 ng/ml
standard. Make 1:2 serial dilutions to yield the remaining standards. Store at 4°C
for no longer than 2 weeks.

Assay Procedure:
1. Label test tubes (12x75 mm)
2. Add PBSG, standard, and samples to tubes (in duplicate) as follows:
PBSG(ul)

Standard/Sample full

Total Radioactivity
300
—
Non-Specific Binding
300
—
P4 Standards
200
0 ng/ml
0.125 ng/ml ,
100
100
0.25 ng/ml
100
100
0.5 ng/ml
100
100
100
1 ng/ml
100
100
2ng/ml
100
4 ng/ml
100
100
8 ng/ml
100
f
100
16 ng/ml
100
TOO
Samples
—
—
3. Pipette 100 ul of antibody solution into all tubes except Totals and NonSpecific B i n d i n g . . ' , - . ,
4. Pipette 100 ul 3H progesterone into all tubes and vortex. Cover tubes with
parafilm and incubate at 4°C overnight.
Following incubation period:
l.Pre-chill centrifuge to 4°C.
2. Place racks of test tubes into ice water baths.
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3. Keep charcoal solution uniformly suspended by stirring vigorously in an ice
bath. With a repeat pipeter, add 750 ul cpld charcoal suspension as quickly as
possible to all tubes EXCEPT Totals, which get 750 ul PBSG.
4. Start a 10 minute timer just before adding charcoal to fist tube.
5. Place tubes into a 4°C centrifuge.
6. Once timer beeps, centrifuge samples at 1500 x g for 10 minutes.
7. Decant supernatant (and all Totals) into scintillation vials.
8. Add 4.5 ml Ready Safe counting cocktail (Beckman Instruments; Fullerton,
CA), cap vials, number vials, and invert twice.
9. Determine counts using a liquid scintillation counter (LS 6000IC; Beckman
Instruments; Port Jefferson, NY).

APPENDIX H. PROPOSED CELL MODEL OF LUTEOLYSIS

ENDOTHELIAL CELL
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APPENDIX I. PROGESTERONE STANDARD ERROR OF
MEANS FOR FIGURE 13
Hour
0
4
8
-N 12
16
20
21
22
23
24
25
26
27
28
29
30
, 31

+/-SEM

Hour

+/-SEM

0.2382
0.3037
0.2162
0.2982
0.3615
0.2197
0.2177
0.1828
0.2360
0.2807
0.3791
0.2864
0.3565
0.3020
0.3205
0.3021
0.3449

32
33
34
35
36
37
38
39
40
41
42 .
43
44
45
46
47
48

0.5120
0.1481
0.2121
0.2634
0.2095
0.2300
0.2810
0,3731
0.3975
0.5840
0.5428
0.7318
0.8495
0.8449
0.6509
0.8107
0.9738
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APPENDIX J. PROGESTERONE CONCENTRATIONS OF
SHEEP 2 VS MEAN PROGESTERONE OF SHEEP 1,3,4
Piasma P<, Concentrations Following Three Infusions of PGF^
'.a Q _

!
!
m
m
o

(Triangle in«tkates tane oflnteectomy relative ro third uifuaou of PGPjJ
•0 4-

0 2 4 S e 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 30
Time {Hours Relative to the First Infusion of FGFj.,,)
Appendix J: Mean plasma progesterone concentrations of sheep 1, 3, & 4 vs individual
plasma progesterone concentration of sheep 2 following three infusions of PGF2a.
Bracketed arrows indicate infusions of PGF2a. ~"
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APPENDIX K. IRB (IACUC) FORM
University of Connecticut
Office of Research Compliance
Margaret J. Sekellick, Ph.D.
IAOJCChair
860-486-3616
marearet.sekdlick(auconn.edu
DATE:

June 23,2008

TO:

John A. McCracken

.

Department of Animal Science, Unit 4040
FROM:

MargaretJ. Sekellick, PhD.

SUBJECT:

Notice of IACUC Approval

'

This letter serveslas written notice ofanjmaluse APPROVAL by thelACUC. Please hotethat at the April 22,2008
IACUCmeeting, the IACUC determined that the protocol re<niired modifications to secure arpro^
addressed. Pleasereferto the assigned protocol number for all animal orders and future correspondence with the IACUC;
cage cards should contain this protocol number. Please, advise us in the future of any necessary corrections orrevisionsby
completing the appropriate form at http://www.iacuc.uconn.edu/forms.html.
Please Note: All investigators are required to makestudy iwwds available for inspection durmg normal business
hours. If study records are kept in locked facilities, a meinberofthe research staffmust be designated as the official conte^
person for record inspection.
W
This institution has an Assurance of Compliance onfilewimfteOfficeofl^boTOtoryAmmal Welfare, National
Institutes of Health (Assuraitce#A3124-4)I,2/28/12).
Funding Source: (I) USDA. ffiX JCRF
AH animal use protocols must bereviewedannually from the date of IACUC approval; you will receive an e-mail
notice requesting an annual update. Thank you for your efforts to help keep the University in compliance with all animal
welfare regulations.
'*
'
*Title:

l"Year: "Molecular Mediators of Luteolysls"
Sheep

Dale Approved:

June 23,2008-June 22,200?

Protocol Number:

A08-015

cc:

Daniel Fletcher, Department of Animal Science/Unit 4040
Richard Sirhoriiello, Office of Animal Research Services/Unit 3150
Sheryl Lohman, Office of Animal Research Services/Unit 3 ISO
William Field, Environmental Health and Safety/Unit 4097

An Equal Opportunity Employer
^Wj7hitney Road Extension Unit 1246
Stotrs, Connecticut 06269-1246
Telephone: (860) 486.8802
Facsimile: (860) 486-1044
web: http://www.compliance.uconn.edu .

185

